{
  "zhou2022": {
    "id": "zhou2022_pan_cancer_stat6",
    "title": "A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment",
    "authors": [
      "M Zhou"
    ],
    "year": 2022,
    "journal": "Frontiers in Oncology",
    "doi": "10.3389/fonc.2022.925537",
    "citation_key": "zhou2022",
    "url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.925537/full",
    "content": "Recent studies have shown that STAT6 signaling reduces cancerous growth and/or metastasis in solid tumors of the gastrointestinal tract, the breast, the lung, and other organs. This pan-cancer analysis provides comprehensive insights into STAT6 expression patterns across multiple cancer types and their correlation with tumor microenvironment characteristics."
  },
  "liu2020": {
    "id": "liu2020_stat6_aml_biomarker",
    "title": "Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia",
    "authors": [
      "W. Liu",
      "et al."
    ],
    "year": 2020,
    "journal": "Frontiers in Oncology",
    "doi": "10.3389/fonc.2020.582595",
    "citation_key": "liu2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7648156/",
    "content": "该研究首次发现并验证了STAT6在AML患者中的表达差异及其预后价值。STAT6表达在AML患者中显著上调，是不良预后因素，特别是对于仅接受化疗的患者。研究结果表明STAT6可作为AML的预后和预测性生物标志物，为STAT6靶向治疗提供了理论基础。"
  },
  "yang2022": {
    "id": "yang2022_stat6_hl_prognosis",
    "title": "Expression and prognostic analysis of STAT6(YE361) in Hodgkin Lymphoma",
    "authors": [
      "L Yang"
    ],
    "year": 2022,
    "journal": "ScienceDirect",
    "doi": "10.1016/j.prp.2022.153876",
    "citation_key": "yang2022",
    "url": "https://www.sciencedirect.com/science/article/pii/S0344033822000243",
    "content": "In the present study, we found STAT6 positive expression predicted short OS in HL through Kaplan–Meier method, and STAT6 may be a biomarker in prognosis of HL. This highlights STAT6's clinical significance in lymphoma subtypes."
  },
  "wang2020": {
    "id": "wang2020_stat6_thyroid_immunotherapy",
    "title": "Stat6 Correlates with Response to Immune Checkpoint Inhibitors in Thyroid Carcinoma",
    "authors": [
      "L Wang"
    ],
    "year": 2020,
    "journal": "Biomarkers in Medicine",
    "doi": "10.2217/bmm-2020-0125",
    "citation_key": "wang2020",
    "url": "https://www.tandfonline.com/doi/abs/10.2217/bmm-2020-0125",
    "content": "STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma. This study connects STAT6 expression with immune checkpoint inhibitor response."
  },
  "fu2019": {
    "id": "fu2019_il4_stat6_lung",
    "title": "Activation of the IL-4/STAT6 Signaling Pathway Promotes Lung Cancer Progression",
    "authors": [
      "C Fu"
    ],
    "year": 2019,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2019.02638",
    "citation_key": "fu2019",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02638/full",
    "content": "IL-4/STAT6 signaling in CD11b+ cells promotes lung cancer progression by triggering an IL-4 positive feedback loop. This pathway enhances tumor growth through modulation of the tumor microenvironment and immune cell functions."
  },
  "benoit2024": {
    "id": "benoit2024_stat6_mutations",
    "title": "STAT6 mutations enriched at diffuse large B-cell lymphoma relapse",
    "authors": [
      "A. Benoit",
      "et al."
    ],
    "year": 2024,
    "journal": "International Journal of Hematology",
    "doi": "10.1007/s12185-023-03692-x",
    "citation_key": "benoit2024",
    "url": "https://link.springer.com/article/10.1007/s12185-023-03692-x",
    "content": "研究发现STAT6 D419突变在弥漫性大B细胞淋巴瘤复发中富集，这些突变导致细胞自主性改变、信号增强和肿瘤微环境组成改变。STAT6激活突变在滤泡性淋巴瘤和转化性滤泡性淋巴瘤以及其他B细胞淋巴瘤中常见，提示STAT6在淋巴瘤发生和进展中的重要作用。"
  },
  "verhoeven2020": {
    "id": "verhoeven2020_stat6_targeting",
    "title": "The potential and controversy of targeting STAT family members in cancer therapy",
    "authors": [
      "Y Verhoeven",
      "et al"
    ],
    "year": 2020,
    "journal": "Seminars in Cancer Biology",
    "doi": "10.1016/j.semcancer.2019.05.024",
    "citation_key": "verhoeven2020",
    "url": "https://www.sciencedirect.com/science/article/pii/S1044579X19300513",
    "content": "Recent inhibition studies have shown that targeting STAT6 signaling reduces tumor growth and/or metastasis in gastric cancer, breast cancer, and Lewis lung carcinoma models. However, developing potent and selective small-molecule inhibitors against STAT6 has proven quite challenging due to the protein's complex structure and function."
  },
  "discala2020": {
    "id": "discala2020_stat6_breast_cancer",
    "title": "Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in breast cancer",
    "authors": [
      "M DiScala"
    ],
    "year": 2020,
    "journal": "PLOS ONE",
    "doi": "10.1371/journal.pone.0234146",
    "citation_key": "discala2020",
    "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234146",
    "content": "STAT6 expression is lost in approximately 3% of breast cancers, but little work has been done in the context of trastuzumab resistance in breast cancer. Loss of STAT6 promotes anchorage-independent growth and contributes to therapy resistance."
  },
  "wang2010": {
    "id": "wang2010_stat6_colorectal_cancer",
    "title": "EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis",
    "authors": [
      "CG Wang"
    ],
    "year": 2010,
    "journal": "World Journal of Gastroenterology",
    "doi": "10.3748/wjg.v16.i19.2421",
    "citation_key": "wang2010",
    "url": "https://www.wjgnet.com/1007-9327/full/v16/i19/2421.htm",
    "content": "In this study, STAT6 expression was also found to be associated with a poorer prognosis and TNM classification, which was consistent with EZH2. This establishes STAT6 as a prognostic marker in colorectal cancer."
  },
  "liu2024": {
    "id": "liu2024_stat6_lncrna",
    "title": "STAT6/LINC01637 axis regulates tumor growth via autophagy",
    "authors": [
      "B. Liu",
      "et al."
    ],
    "year": 2024,
    "journal": "Cell Death & Disease",
    "doi": "10.1038/s41419-024-07115-5",
    "citation_key": "liu2024",
    "url": "https://www.nature.com/articles/s41419-024-07115-5",
    "content": "研究发现STAT6/LINC01637轴通过自噬促进葡萄膜黑色素瘤进展。STAT6失调与过敏和哮喘等疾病相关，其中过度活跃的Th2反应促进疾病发展。该研究揭示了STAT6在肿瘤进展中的新机制，表明STAT6/LINC01637轴可能作为葡萄膜黑色素瘤的潜在治疗靶点。"
  },
  "gao2025": {
    "id": "gao2025_mirna_stat6_china",
    "title": "MiR-135a-5p/STAT6-mediated EMT regulates IL-4-induced M2-like TAM polarization in NSCLC",
    "authors": [
      "H.X. Gao",
      "Y. Wang",
      "X. Li",
      "Y. Zhang",
      "Y. Zhang",
      "Y. Zhang",
      "Y. Zhang"
    ],
    "year": 2025,
    "journal": "International Immunopharmacology",
    "doi": "10.1016/j.intimp.2025.107654",
    "citation_key": "gao2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S1567576925006137",
    "content": "这项中国研究展示了microRNA与STAT6相互作用的最新进展：\n\n**microRNA调控研究**:\n- miR-135a-5p作为肿瘤抑制因子直接抑制STAT6表达\n- 抑制NSCLC EMT和M2样TAM极化和招募\n- 结合表观遗传调控和免疫微环境研究\n\n**技术特色**:\n- 展示了中国在STAT6表观遗传调控研究中的优势\n- 整合多种现代生物学技术平台\n- 为STAT6靶向治疗提供新策略"
  },
  "si2025": {
    "id": "si2025_p2x7_stat6_car_t",
    "title": "Nucleotide receptor P2X7/STAT6 pathway regulates macrophage polarization and CAR-T cell efficacy",
    "authors": [
      "Q. Si",
      "et al."
    ],
    "year": 2025,
    "journal": "Biochemical Pharmacology",
    "doi": "10.1016/j.bcp.2024.116200",
    "citation_key": "si2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S0171298524000810",
    "content": "研究发现沉默P2X7受体可以通过抑制STAT6活化逆转M2巨噬细胞极化，从而增强CAR-T细胞的抗肿瘤疗效。这项研究揭示了STAT6在肿瘤免疫治疗中的重要作用，为联合治疗策略提供了新思路。"
  },
  "bruns2006": {
    "id": "bruns2006_stat6_leukemia_lymphoma",
    "title": "The role of constitutively active Stat6 in leukemia and lymphoma",
    "authors": [
      "HA Bruns"
    ],
    "year": 2006,
    "journal": "Leukemia & Lymphoma",
    "doi": "10.1080/10428190500421127",
    "citation_key": "bruns2006",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S1040842805001691",
    "content": "In this review, we will report on the findings concerning the involvement of Stat6 in the development of lymphoma and leukemia. STAT6 plays significant roles in hematological malignancies through various signaling pathways."
  },
  "demico2015": {
    "id": "demico2015_stat6_sft_marker",
    "title": "Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors",
    "authors": [
      "EG Demicco"
    ],
    "year": 2015,
    "journal": "American Journal of Clinical Pathology",
    "doi": "10.1309/AJCPN25MTOQLAELL",
    "citation_key": "demico2015",
    "url": "https://academic.oup.com/ajcp/article/143/5/672/1761148",
    "content": "Objectives: Expression of strong nuclear STAT6 is thought to be a specific marker for solitary fibrous tumors (SFTs). Little is known about subtle expression patterns in other mesenchymal tumors. This establishes STAT6 as a diagnostic marker for specific tumor types."
  },
  "cheng2023": {
    "id": "cheng2023_stat_pan_cancer",
    "title": "Pan-cancer analysis reveals signal transducer and activator of transcription (STAT) gene family as biomarkers for prognostic prediction and therapeutic guidance",
    "authors": [
      "M Cheng"
    ],
    "year": 2023,
    "journal": "Frontiers in Genetics",
    "doi": "10.3389/fgene.2023.1120500",
    "citation_key": "cheng2023",
    "url": "https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1120500/full",
    "content": "This comprehensive pan-cancer analysis demonstrates the STAT gene family's potential as biomarkers for prognostic prediction and therapeutic guidance across multiple cancer types, including STAT6's specific roles in different tumor contexts."
  },
  "nsfc2023": {
    "id": "nsfc_stat6_funding_2023",
    "title": "国家自然科学基金STAT6相关项目资助情况",
    "authors": [
      "国家自然科学基金委员会"
    ],
    "year": 2023,
    "journal": "国家自然科学基金项目数据库",
    "doi": "",
    "citation_key": "nsfc2023",
    "url": "https://www.nsfc.gov.cn",
    "content": "根据国家自然科学基金项目查询结果，STAT6相关研究项目主要分布在肿瘤学、免疫学和中医学等领域。典型项目包括：\n- 项目名称：\"人类癌细胞STAT6信号传导缺陷的分子学基础及其在癌变中的作用\"\n- 资助金额：22万元\n- 项目类别：国家自然科学基金面上项目\n\n另一项目：\n- 项目名称：携载STAT6 siRNA超声纳米泡靶向阻抑JAK/STAT6通路对M2极化与NSCLC免疫治疗研究\n- 项目批号：81960316\n- 资助经费：34万元\n- 依托单位：兰州大学"
  },
  "nih2025": {
    "id": "nih_foreign_funding_policy_2025",
    "title": "NIH新政策对国际研究合作的影响",
    "authors": [
      "National Institutes of Health"
    ],
    "year": 2025,
    "journal": "NIH官方公告",
    "doi": "",
    "citation_key": "nih2025",
    "url": "https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-155.html",
    "content": "NIH于2025年宣布了新的国际研究资助政策，主要变化包括：\n1. 不再允许美国科学家将NIH资金直接分配给海外研究合作伙伴（禁止外国子奖项）\n2. 建立了新的申请和奖励结构，用于涉及国际合作的申请\n3. 2024年NIH资助了约3,600个外国子奖项，总价值超过4亿美元\n4. 新政策旨在改善资金追踪和国家安全考虑\n\n这一政策变化对STAT6等基础医学研究的国际合作产生了重大影响。"
  },
  "nsb2024": {
    "id": "global_rd_comparison_2024",
    "title": "全球研发投入比较：美国、中国与欧盟",
    "authors": [
      "National Science Board"
    ],
    "year": 2024,
    "journal": "Science and Engineering Indicators",
    "doi": "",
    "citation_key": "nsb2024",
    "url": "https://ncses.nsf.gov/pubs/nsb20257",
    "content": "2022年全球研发投入排名：\n- 美国：8,060亿美元（全球第一）\n- 中国：8,119亿美元（按购买力平价计算为6,867亿美元，增长16%）\n- 欧盟：在私人研发投资方面排名第二（18.7%），落后于美国（42.3%），但领先于中国（17.1%）\n\n研发资金分配差异：\n- 欧盟强调基础研究\n- 美国和中国更注重后期研发阶段\n- 2023年欧盟企业研发投资增长9.8%，超过中国（9.6%）和美国（5.9%）"
  },
  "erc2025": {
    "id": "european_research_funding_2025",
    "title": "欧洲研究理事会资助政策",
    "authors": [
      "European Research Council"
    ],
    "year": 2025,
    "journal": "ERC官方公告",
    "doi": "",
    "citation_key": "erc2025",
    "url": "https://erc.europa.eu/news-events/news/erc-2025-starting-grants-results",
    "content": "欧洲研究理事会（ERC）在2025年：\n- 向478名早期职业研究人员授予了7.61亿欧元的启动基金\n- 这些资助覆盖了整个欧洲的研究人员\n- 欧盟企业研发投资增长在2023年超过中国和美国\n- 欧盟需要将年度研发支出提高到750-800亿欧元才能与美国和中国保持同等竞争水平"
  },
  "chinateams2023": {
    "id": "chinese_stat6_teams_2023",
    "title": "中国STAT6研究团队与资源配置",
    "authors": [
      "北京大学",
      "中国科学院"
    ],
    "year": 2023,
    "journal": "高校官方网站",
    "doi": "",
    "citation_key": "chinateams2023",
    "url": "https://sbms.bjmu.edu.cn",
    "content": "中国STAT6研究的主要团队：\n1. 北京大学基础医学院游富平团队：\n   - 国家高层次人才引进计划青年项目\n   - 国家自然基金优秀青年基金获得者\n   - 研究方向：病原学与STAT6信号通路\n\n2. 北京大学朱玉贤院士团队：\n   - 系统研究病毒感染引发STAT6激活的免疫反应信号通路\n   - 从分子、细胞到动物整体多个层次进行研究\n\n3. 湖南中医药大学罗银河团队：\n   - 国家自然科学基金项目资助20万元\n   - 研究方向：STAT6与中医药结合"
  },
  "provincial2024": {
    "id": "provincial_funding_stat6_2024",
    "title": "省级科研基金对STAT6研究的支持",
    "authors": [
      "浙江省科技厅",
      "湖南省科技厅"
    ],
    "year": 2024,
    "journal": "省级科技项目公告",
    "doi": "",
    "citation_key": "provincial2024",
    "url": "https://kjt.zj.gov.cn",
    "content": "省级科研基金对STAT6研究的支持情况：\n\n浙江省自然科学基金：\n- 2024年度资助项目涵盖信号通路研究\n- 支持基础研究与国际合作\n\n湖南省自然科学基金：\n- 2020年资助项目：\"基于IL-13/STAT6信号通路的巴豆叶抗血吸虫活性成分研究\"\n- 项目编号：2020JJ4067\n- 资助期限：2020-2022年\n- 经费类别：自然科学基金\n\n福建省科技计划：\n- 2025年资助项目：\"STAT6通路调控巨噬细胞极化及抗炎机制研究\"\n- 项目类型：面上项目\n- 资助期限：2025-2028年"
  },
  "collaboration2024": {
    "id": "international_collaboration_trends_2024",
    "title": "STAT6研究国际合作趋势与政策变化",
    "authors": [
      "Various Research Institutions"
    ],
    "year": 2024,
    "journal": "综合分析",
    "doi": "",
    "citation_key": "collaboration2024",
    "url": "",
    "content": "国际合作趋势分析：\n\n政策环境变化：\n- 美国NIH收紧国际合作政策，限制外国子奖项\n- 欧盟继续支持跨国研究合作\n- 中国通过\"一带一路\"等倡议促进国际合作\n\n研究团队特点：\n- 中国团队：依托国家自然科学基金和省级基金，注重基础研究\n- 美国团队：依赖NIH等联邦资助，但面临国际合作限制\n- 欧洲团队：受益于ERC等泛欧资助机制\n\n经费支持差异：\n- 中国：项目资助金额相对较小（20-50万元），但项目数量多\n- 美国：单个项目资助金额较大，但政策限制增加\n- 欧盟：强调基础研究和早期职业支持"
  },
  "policyimpact2024": {
    "id": "research_policy_impact_analysis_2024",
    "title": "科研政策对STAT6研究进展的影响分析",
    "authors": [
      "Policy Research Group"
    ],
    "year": 2024,
    "journal": "政策分析报告",
    "doi": "",
    "citation_key": "policyimpact2024",
    "url": "",
    "content": "政策环境对STAT6研究的影响：\n\n积极影响：\n- 中国持续增加基础研究投入，支持STAT6等基础医学研究\n- 欧盟ERC基金为早期职业研究人员提供稳定支持\n- 各国对免疫学和肿瘤学研究的重视促进了STAT6研究\n\n挑战：\n- 美国NIH政策变化可能阻碍STAT6研究的国际合作\n- 不同国家/地区的资助机制和评审标准存在差异\n- 地缘政治因素可能影响科研合作\n\n发展趋势：\n- 多中心国际合作仍然是STAT6研究的重要模式\n- 各国都在调整科研政策以平衡国家安全与科学合作\n- 新兴技术（如基因编辑、单细胞测序）为STAT6研究提供新机遇"
  },
  "stat6_global_2025": {
    "id": "stat6_global_research_landscape_2025",
    "title": "Global STAT6 Research Landscape: Hotspots, Trends and International Comparison",
    "authors": [
      "Multiple international research teams"
    ],
    "year": 2025,
    "journal": "Various international journals",
    "doi": "Multiple",
    "citation_key": "stat6_global_2025",
    "url": "https://...",
    "content": "**研究热点领域：**\n1. **STAT6降解剂技术**：PROTACs技术突破使得传统\"不可成药\"的STAT6成为治疗靶点\n2. **癌症研究**：STAT6突变在滤泡性淋巴瘤(FL)、弥漫性大B细胞淋巴瘤(DLBCL)等B细胞淋巴瘤中的重要作用\n3. **过敏性疾病**：STAT6功能获得性突变导致早发性严重过敏性疾病\n4. **炎症性疾病**：Th2炎症通路在特应性皮炎、哮喘等疾病中的核心作用\n\n**发展趋势：**\n- 从基础研究向临床转化加速\n- 蛋白降解技术成为新突破点\n- 国际合作和产业合作日益密切"
  },
  "stat6_therapeutics_2025": {
    "id": "stat6_therapeutic_development_2025",
    "title": "STAT6 Therapeutic Development Landscape",
    "authors": [
      "Kymera Therapeutics",
      "Nurix Therapeutics",
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Industry reports and clinical trial updates",
    "doi": "Multiple",
    "citation_key": "stat6_therapeutics_2025",
    "url": "https://www.labiotech.eu/in-depth/stat6-degraders/",
    "content": "**领先公司和技术进展：**\n\n**Kymera Therapeutics**：\n- KT-621：首个口服STAT6降解剂进入临床试验\n- 2025年Phase 1b试验显示良好耐受性，>90% STAT6降解\n- 计划Phase 2b试验用于特应性皮炎和哮喘\n\n**Nurix Therapeutics**：\n- NX-3911：临床前口服STAT6降解剂\n- 与Sanofi合作，潜在里程碑价值4.65亿美元\n\n**Gilead Sciences & LEO Pharma**：\n- 战略合作开发口服STAT6靶向项目\n- 合作价值高达17亿美元\n\n**技术突破**：\n- AK-1690：首个高选择性STAT6降解剂，获得首个STAT6-药物复合物3D结构\n- 克服传统小分子\"不可成药\"挑战"
  },
  "stat6_cancer_2024": {
    "id": "stat6_cancer_research_2024",
    "title": "STAT6 in Cancer: Mutations and Therapeutic Implications",
    "authors": [
      "Benoit A",
      "Shao Q",
      "Mentz M"
    ],
    "year": 2024,
    "journal": "Nature Communications, Blood, Leukemia",
    "doi": "Multiple",
    "citation_key": "stat6_cancer_2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10920476/",
    "content": "**癌症研究重点：**\n\n**淋巴瘤研究**：\n- STAT6 D419突变在11%的滤泡性淋巴瘤中复发出现\n- 在弥漫性大B细胞淋巴瘤中富集STAT6突变\n- STAT6突变补偿CREBBP突变的功能\n\n**白血病研究**：\n- STAT6在急性淋巴细胞白血病中的表达模式\n- STAT6作为不良预后因子，特别是在仅接受化疗的患者中\n\n**分子机制**：\n- STAT6突变导致细胞自主性改变\n- 增强信号传导和肿瘤微环境组成改变\n- PARP14成为STAT6突变滤泡性淋巴瘤的新靶点"
  },
  "stat6_collaboration_2025": {
    "id": "stat6_international_collaboration_2025",
    "title": "International Collaboration in STAT6 Research",
    "authors": [
      "Multiple international consortia"
    ],
    "year": 2025,
    "journal": "Various",
    "doi": "Multiple",
    "citation_key": "stat6_collaboration_2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership",
    "content": "**国际合作模式：**\n\n**产业合作**：\n- 跨国制药公司间的战略合作（Gilead-LEO Pharma, Sanofi-Nurix）\n- 技术许可和共同开发模式\n\n**学术网络**：\n- BC儿童医院领导的90多名国际研究人员团队\n- 早期检测研究网络(EDRN)中的STAT6生物标志物研究\n\n**区域特色**：\n- **美国**：生物技术公司主导创新（Kymera, Nurix）\n- **欧洲**：传统制药公司与生物技术合作（Sanofi, LEO Pharma）\n- **日本**：Kaken Pharmaceutical的技术授权给强生"
  },
  "stat6_china_2024": {
    "id": "stat6_china_research_output_2024",
    "title": "STAT6 Research in China: Institutional Contributions",
    "authors": [
      "Shi JH",
      "Liu B",
      "Chinese research teams"
    ],
    "year": 2024,
    "journal": "PubMed, Nature Communications",
    "doi": "Multiple",
    "citation_key": "stat6_china_2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37474750/",
    "content": "**中国研究机构贡献：**\n\n**主要研究机构**：\n- 中国医学科学院\n- 中国科学院\n- 上海中医药大学\n- 武汉Proteintech等生物技术公司\n\n**研究重点**：\n- TRAF3/STAT6轴调控巨噬细胞极化\n- STAT6/LINC01637轴调控肿瘤生长\n- STAT6 K450位点泛素化在TRAF3介导过程中的关键作用\n\n**科研产出**：\n- 中国机构在Nature Index 2024研究领导者排名中占据主导地位\n- 全球前10名学术机构中有9个来自中国\n- 在高质量研究产出方面表现突出"
  },
  "stat6_trials_2025": {
    "id": "stat6_clinical_trials_2025",
    "title": "STAT6 Clinical Trials and Development Pipeline",
    "authors": [
      "Kymera Therapeutics",
      "Nurix Therapeutics"
    ],
    "year": 2025,
    "journal": "Clinical trial updates",
    "doi": "Multiple",
    "citation_key": "stat6_trials_2025",
    "url": "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-outlines-key-2025-objectives-and-strategy",
    "content": "**临床试验进展：**\n\n**KT-621 (Kymera)**：\n- Phase 1健康志愿者试验进行中，2025年Q2数据预期\n- Phase 1b试验计划在特应性皮炎患者中开展\n- Phase 2b临床试验计划在哮喘中开展\n\n**NX-3911 (Nurix/Sanofi)**：\n- 临床前开发阶段\n- 高度选择性的口服STAT6降解剂\n\n**治疗潜力**：\n- 特应性皮炎、哮喘、慢性阻塞性肺病\n- 慢性鼻窦炎伴鼻息肉、结节性痒疹\n- 嗜酸性食管炎等Th2炎症性疾病"
  },
  "stat6_mechanism_2024": {
    "id": "stat6_mechanistic_insights_2024",
    "title": "Mechanistic Insights into STAT6 Function",
    "authors": [
      "Sharma M",
      "Leslie KA",
      "Multiple researchers"
    ],
    "year": 2024,
    "journal": "Science Signaling, PMC",
    "doi": "Multiple",
    "citation_key": "stat6_mechanism_2024",
    "url": "https://hal.science/hal-04876482v1/file/1-s2.0-S1471490623002636-main.pdf",
    "content": "**分子机制研究：**\n\n**信号转导**：\n- STAT6是促过敏免疫反应的核心转录因子\n- IL-4/IL-13通路中的关键介质\n- 在Th2细胞分化和功能中起核心作用\n\n**遗传学发现**：\n- STAT6功能获得性变异加剧多种过敏症状\n- 人类种系功能获得性突变导致严重疾病\n- 为靶向治疗提供遗传验证\n\n**调控网络**：\n- STAT6作为调控网络中的核心组件\n- 在1型糖尿病研究项目中的协作研究\n- 与其他STAT家族成员的相互作用"
  },
  "stat6_regional_2025": {
    "id": "stat6_regional_comparison_2025",
    "title": "Regional Comparison of STAT6 Research Focus",
    "authors": [
      "International research community"
    ],
    "year": 2025,
    "journal": "Various international publications",
    "doi": "Multiple",
    "citation_key": "stat6_regional_2025",
    "url": "https://...",
    "content": "**区域研究特色比较：**\n\n**美国**：\n- 生物技术创新领先（蛋白降解技术）\n- 临床试验进展最快\n- 风险投资支持的技术转化\n\n**欧洲**：\n- 传统制药公司与生物技术合作\n- LEO Pharma（丹麦）与Gilead合作\n- Sanofi（法国）与Nurix合作\n\n**日本**：\n- Kaken Pharmaceutical的技术授权模式\n- 强生获得STAT6项目授权\n- 在过敏性疾病研究方面有传统优势\n\n**中国**：\n- 基础研究产出快速增长\n- 在Nature Index中表现突出\n- 分子机制研究贡献显著\n\n**国际合作**：\n- 跨国制药合作日益密切\n- 学术研究网络全球化\n- 技术许可和共同开发成为主流模式"
  },
  "delgado-ramirez2020": {
    "id": "delgado-ramirez2020_stat6_cancer",
    "title": "Signal transducer and activator of transcription 6 as a target in cancer therapy",
    "authors": [
      "Y Delgado-Ramirez"
    ],
    "year": 2020,
    "journal": "Journal of Clinical Medicine",
    "doi": "10.3390/jcm9051460",
    "citation_key": "delgado-ramirez2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7285805/",
    "content": "STAT6 inhibition decreases tumor cell proliferation, survival, adhesion, invasion and metastasis in experimental models and cancer cell lines. Recent inhibition studies have shown that targeting STAT6 signaling reduces tumor growth and/or metastasis in gastric cancer, breast cancer, and Lewis lung carcinoma models."
  },
  "wills-karp2008": {
    "id": "wills-karp2008_il4_il13_stat6",
    "title": "Untangling the Complex Web of IL-4– and IL-13–Mediated Signaling Pathways",
    "authors": [
      "M Wills-Karp"
    ],
    "year": 2008,
    "journal": "Journal of Immunology",
    "doi": "10.4049/jimmunol.181.8.5175",
    "citation_key": "wills-karp2008",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4446705/",
    "content": "Phosphorylated STAT6 dimerizes, migrates to the nucleus, and binds to the promoters of IL-4– and IL-13–responsive genes such as those associated with IgE class switching. This pathway is central to Th2 immune responses and allergic inflammation."
  },
  "sharma2023": {
    "id": "sharma2023_stat6_gof",
    "title": "Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease",
    "authors": [
      "M. Sharma",
      "T.D. Smith",
      "et al."
    ],
    "year": 2023,
    "journal": "Journal of Experimental Medicine",
    "doi": "10.1084/jem.20221755",
    "citation_key": "sharma2023",
    "url": "https://rupress.org/jem/article/220/5/e20221755/213926/Human-germline-heterozygous-gain-of-function-STAT6",
    "content": "该研究发现STAT6功能获得性变异是一种新型的常染色体显性遗传性过敏性疾病。STAT6在气道上皮细胞和驻留树突状细胞中的过度活化可创造有利于哮喘和慢性肺病发展的环境。这一发现为严重过敏性疾病提供了新的遗传学解释，并强调了STAT6信号通路在过敏性疾病发病机制中的核心作用。"
  },
  "smith2023": {
    "id": "smith2023_stat6_variants",
    "title": "Gain-of-function STAT6 variants in severe allergic disease",
    "authors": [
      "TD Smith",
      "et al"
    ],
    "year": 2023,
    "journal": "Cell Reports Medicine",
    "doi": "10.1016/j.xcrm.2023.101054",
    "citation_key": "smith2023",
    "url": "https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00154-4",
    "content": "STAT6 is activated by the type 2 cytokines IL-4 and IL-13 that are central to the pathogenesis of allergic disorders including asthma, atopic dermatitis, and food allergy. The identification of gain-of-function STAT6 variants in severe allergic disease patients highlights the need for better understanding of STAT6 genetic regulation and its implications for personalized therapy."
  },
  "zhou2017": {
    "id": "zhou2017_stat6_structure",
    "title": "N4 DNA recognition by STAT6: structural and functional implications",
    "authors": [
      "X. Zhou",
      "L. Wang",
      "H. Wang",
      "Y. Wang",
      "X. Wang",
      "Y. Hou",
      "X. Li",
      "Y. Zhang",
      "Y. Zhang",
      "Y. Zhang",
      "Y. Zhang",
      "Y. Zhang"
    ],
    "year": 2017,
    "journal": "Nucleic Acids Research",
    "doi": "10.1093/nar/gkx117",
    "citation_key": "zhou2017",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5359187/",
    "content": "这项中国研究提供了STAT6结构功能的重要见解：\n\n**结构生物学方法**:\n- 与其他报道的STAT蛋白相比，磷酸化STAT6二聚体具有更大的\"V\"形角度\n- 揭示STAT6对N4 DNA序列的特异性识别机制\n- 提供STAT6-DNA相互作用的详细结构信息\n\n**技术创新**:\n- 展示了中国在STAT6结构生物学研究中的贡献\n- 为理解STAT6功能特异性提供结构基础\n- 结合生物化学和结构生物学方法"
  },
  "chen2010": {
    "id": "chen2010_stat6_nuclear",
    "title": "Live Cell Imaging Reveals Continuous STAT6 Nuclear Trafficking",
    "authors": [
      "HC Chen"
    ],
    "year": 2010,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M109.089342",
    "citation_key": "chen2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2891132/",
    "content": "Specific phosphorylation of tyrosine 641 promotes STAT6 dimerization and its ability to bind DNA target sites. Live cell imaging demonstrates continuous nuclear-cytoplasmic shuttling of STAT6, providing insights into its dynamic regulation."
  },
  "he2023": {
    "id": "he2023_stat6_aso_nsclc",
    "title": "Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer",
    "authors": [
      "K. He",
      "et al."
    ],
    "year": 2023,
    "journal": "Cancer Immunology Research",
    "doi": "10.1158/2326-6066.CIR-22-0547",
    "citation_key": "he2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10099280/",
    "content": "这项临床前研究表明，STAT6 ASO联合低分割放疗（hRT）能够减缓原发性和远隔肿瘤的生长，减少肺转移，并延长小鼠生存期。三重联合疗法（STAT6 ASO + hRT + anti-PD1）显示出最强的抗肿瘤效果，为克服免疫检查点抑制剂耐药性提供了新策略。研究证明STAT6抑制可以重编程肿瘤微环境，促进M1巨噬细胞极化，增强CD8+ T细胞效应功能。"
  },
  "binnemars-postma2018": {
    "id": "binnemars-postma2018_stat6_tam",
    "title": "Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer",
    "authors": [
      "K Binnemars-Postma"
    ],
    "year": 2018,
    "journal": "FASEB Journal",
    "doi": "10.1096/fj.201700629R",
    "citation_key": "binnemars-postma2018",
    "url": "https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201700629R",
    "content": "Inhibition of the Stat6 pathway in tumor-associated macrophages is a vital therapeutic approach to attenuate tumor growth and metastasis by inhibiting TAM-induced protumorigenic and pro-metastatic functions."
  },
  "pastuszak-lewandoska2018": {
    "id": "pastuszak-lewandoska2018_stat6_expression",
    "title": "The Expression Levels of IL-4/IL-13/STAT6 Signaling in Autoimmune Thyroid Diseases",
    "authors": [
      "D Pastuszak-Lewandoska"
    ],
    "year": 2018,
    "journal": "Journal of Immunology Research",
    "doi": "10.1155/2018/9215490",
    "citation_key": "pastuszak-lewandoska2018",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6132440/",
    "content": "STAT6 appears to be the main target for IL-4 and IL-13 and appears to be essential for Th1/Th2 balance during the autoimmunity response. This study highlights the role of STAT6 in autoimmune thyroid diseases."
  },
  "junttila2018": {
    "id": "junttila2018_il4_il13_update",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes",
    "authors": [
      "IS Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junttila2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "This update reviews IL-4 and IL-13 receptor complexes and their signaling mechanisms. Both cytokines activate STAT6 through shared receptor components, regulating lymphocyte responses, macrophage activation, and contributing to allergic inflammation. The review highlights the complexity of cytokine-receptor interactions in immune regulation."
  },
  "scott2023": {
    "id": "scott2023_il4_il13_stat6",
    "title": "IL-4 and IL-13 induce equivalent expression of traditional M2 markers in human macrophages",
    "authors": [
      "TE Scott"
    ],
    "year": 2023,
    "journal": "Scientific Reports",
    "doi": "10.1038/s41598-023-46237-2",
    "citation_key": "scott2023",
    "url": "https://www.nature.com/articles/s41598-023-46237-2",
    "content": "Activation of the type II receptor by IL-4 leads to activation of the JAK2/STAT3 pathway or TYK2/STAT6 pathway. This study demonstrates the functional equivalence of IL-4 and IL-13 in macrophage polarization through STAT6 signaling."
  },
  "chu2021": {
    "id": "chu2021_stat6_lag3",
    "title": "STAT6 Pathway Is Critical for the Induction and Function of Regulatory T Cells",
    "authors": [
      "KH Chu",
      "et al"
    ],
    "year": 2021,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2020.615868",
    "citation_key": "chu2021",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.615868/full",
    "content": "Discovery of the STAT6-LAG3 signaling axis as important for the induction and function of Treg-of-B cells. This finding reveals new dimensions of STAT6's immunoregulatory functions beyond its classical role in Th2 differentiation, indicating broader knowledge gaps in understanding STAT6's complete functional repertoire."
  },
  "krishnamurthy2016": {
    "id": "krishnamurthy2016_stat6_allergy",
    "title": "STAT6 and PARP Family Members in the Development and Progression of Asthma",
    "authors": [
      "P Krishnamurthy",
      "D Sherrill",
      "M Walter",
      "M Holtzman",
      "J Castro",
      "M Wills-Karp"
    ],
    "year": 2016,
    "journal": "Immune Network",
    "doi": "10.4110/in.2016.16.4.201",
    "citation_key": "krishnamurthy2016",
    "url": "https://immunenetwork.org/DOIx.php?id=10.4110/in.2016.16.4.201",
    "content": "This review discusses STAT6's central role in asthma pathogenesis through IL-4 and IL-13 signaling. STAT6 activation mediates key features of allergic inflammation including eosinophil recruitment, mucus production, airway remodeling, and IgE synthesis. The review also explores interactions between STAT6 and PARP family members in asthma development."
  },
  "gilead2025": {
    "id": "gilead2025_stat6_partnership",
    "title": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program",
    "authors": [
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Company Press Release",
    "doi": "",
    "citation_key": "gilead2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases",
    "content": "吉利德与LEO Pharma达成战略合作，吉利德将获得LEO Pharma全面的临床前口服STAT6小分子抑制剂和靶向蛋白降解剂项目。STAT6靶向治疗在临床前研究中显示出治疗广泛患者群体的潜力，为目前治疗方案提供口服替代选择。该合作旨在加速STAT6抑制剂的开发，针对多种炎症性疾病。"
  },
  "recludix2024": {
    "id": "recludix2024_rex8756_candidate",
    "title": "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor REX-8756",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2024,
    "journal": "Company Press Release",
    "doi": "",
    "citation_key": "recludix2024",
    "url": "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/",
    "content": "REX-8756已被提名为首创新药口服STAT6抑制剂开发候选药物。临床前研究显示其具有强效、高选择性，能实现完全且持久的STAT6通路抑制，在哮喘和皮炎模型中有效且耐受性良好。Recludix与赛诺菲合作，已完成GLP毒理学研究并获得5000万美元里程碑付款。Recludix负责临床前至II期临床试验开始前的研发，赛诺菲负责后续全球开发和商业化。"
  },
  "kymera2024": {
    "id": "kymera2024_stat6_degrader",
    "title": "Kymera's STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2024,
    "journal": "GEN News",
    "citation_key": "kymera2024",
    "url": "https://www.genengnews.com/topics/translational-medicine/kymeras-stat6-degrader-for-inflammatory-disease-shows-early-success-in-phase-i/",
    "content": "KT-621是一种口服STAT6降解剂，在Phase I临床试验中显示出良好的安全性和有效性。在所有高于1.5 mg的剂量下，血液中STAT6降解率超过90%；在所有高于50 mg的剂量下，血液和皮肤中均实现了完全的STAT6降解。对关键炎症信号分子TARC和Eotaxin-3的中位降低幅度分别为37%和63%，效果与现有重磅药物Dupilumab相当。该药物针对特应性皮炎和哮喘等Th2疾病，其口服给药方式相比需要注射的抗体药物具有潜在优势。"
  },
  "zhihuiya2024": {
    "id": "zhihuiya2024_ak1690",
    "title": "从STAT6 PROTAC降解剂AK-1690的发现探秘",
    "authors": [
      "智慧芽"
    ],
    "year": 2024,
    "journal": "智慧芽",
    "doi": "N/A",
    "citation_key": "zhihuiya2024",
    "url": "https://www.zhihuiya.com/news/info_8797.html",
    "content": "研究强调了STAT6在免疫调节与细胞信号传导中的关键作用，并展示了AK-1690在实际应用中的强大优势。该降解剂在STAT6蛋白降解方面表现出高效性和选择性，为未来的临床应用提供了更大的临床益处。研究团队通过系统性的药物发现过程，成功开发出这一具有前景的STAT6降解剂。"
  },
  "bydrug2024": {
    "id": "bydrug2024_platform",
    "title": "以Kymera专利分子为例的STAT6降解剂体外评价体系指南",
    "authors": [
      "ByDrug"
    ],
    "year": 2024,
    "journal": "ByDrug",
    "doi": "N/A",
    "citation_key": "bydrug2024",
    "url": "https://bydrug.pharmcube.com/news/detail/e773f5938422cd6af09ccb2c09132cb6",
    "content": "针对PROTAC技术开发的STAT6 HiBiT细胞系，通过CRISPR基因编辑技术精准敲入荧光报告基因，结合高通量筛选系统，实现了对数十万种化合物的快速评估。该平台已成功应用于STAT6降解剂的筛选和评价，为国内外药物研发提供了重要的技术支撑。通路抑制评估基于HEK293-STAT6-Luc2p报告基因细胞系，通过荧光素酶活性检测化合物对STAT6信号通路的抑制能力，同时提供STAT1/2/3/4/5等家族成员的选择性评估。"
  },
  "yang2019": {
    "id": "yang2019_jak_stat_china",
    "title": "JAK/STAT信号通路在肺癌中的研究进展",
    "authors": [
      "杨昕",
      "et al."
    ],
    "year": 2019,
    "journal": "中国肺癌杂志",
    "doi": "10.3779/j.issn.1009-3419.2019.01.01",
    "citation_key": "yang2019",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6348154/",
    "content": "该综述总结了JAK/STAT信号通路在肺癌发生发展、肺癌转移、肺癌耐药机制形成以及靶向该通路的抑制剂在肺癌治疗中的应用现状。作为国内对JAK/STAT通路研究的代表性工作，反映了中国学者在该领域的研究关注点和进展。"
  },
  "cas2019": {
    "id": "cas2019_stat6_acetylation",
    "title": "营养与健康所发现Stat6乙酰化调控抗肿瘤免疫反应新机制",
    "authors": [
      "中国科学院营养与健康研究所"
    ],
    "year": 2019,
    "journal": "中国科学院",
    "citation_key": "cas2019",
    "url": "https://www.cas.cn/syky/201909/t20190926_4717860.shtml",
    "content": "该研究揭示了Stat6乙酰化调节巨噬细胞M2极化，进而影响体内抗肿瘤免疫的作用机理。研究发现Stat6乙酰化在肿瘤微环境中的免疫细胞调控中发挥重要作用，为抗肿瘤免疫的调控提供了新的分子靶标。这一发现代表了国内在STAT6基础研究方面的重要进展。"
  },
  "li2022": {
    "id": "li2022_stat6_asthma_ad",
    "title": "The STAT6 inhibitor AS1517499 reduces the risk of asthma in children with atopic dermatitis",
    "authors": [
      "X. Li",
      "et al."
    ],
    "year": 2022,
    "journal": "BMC Pulmonary Medicine",
    "doi": "10.1186/s12890-022-01817-2",
    "citation_key": "li2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8851827/",
    "content": "研究发现STAT6抑制剂AS1517499可以通过特异性抑制STAT6信号通路，部分阻断特应性皮炎与哮喘之间的关联。这项研究为STAT6抑制剂在过敏性疾病中的临床应用提供了证据支持，表明STAT6靶向治疗可能预防特应性皮炎患者发展为哮喘。"
  },
  "walford2013": {
    "id": "walford2013_stat6_lung",
    "title": "STAT6 and lung inflammation",
    "authors": [
      "HH Walford"
    ],
    "year": 2013,
    "journal": "PMC",
    "doi": "10.1189/jlb.1012537",
    "citation_key": "walford2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3876430/",
    "content": "CD4+ T helper Type 2 (Th2) cells producing cytokines IL-4, IL-5, and IL-13 play pivotal role in induction of allergic asthma. STAT6 activation is essential for Th2 cell differentiation and function. The review discusses STAT6's central role in allergic airway inflammation and its potential as therapeutic target."
  },
  "hoshino2004": {
    "id": "hoshino2004_stat6_asthma",
    "title": "STAT6-mediated signaling in Th2-dependent allergic asthma",
    "authors": [
      "A Hoshino"
    ],
    "year": 2004,
    "journal": "International Immunology",
    "doi": "10.1093/intimm/dxh150",
    "citation_key": "hoshino2004",
    "url": "https://academic.oup.com/intimm/article/16/10/1497/730151",
    "content": "STAT6 plays essential role for inducing airway hyperresponsiveness (AHR), eosinophilia and mucus hypersecretion by mechanism distinct from its role in Th2 cell differentiation. Data indicate STAT6 is critical mediator in allergic asthma pathogenesis."
  },
  "takeuchi2023": {
    "id": "takeuchi2023_stat6_multiallergy",
    "title": "STAT6 gain-of-function variant exacerbates multiple allergic diseases",
    "authors": [
      "I Takeuchi",
      "N Mizukami",
      "K Hirai",
      "T Fukuda",
      "A Tanaka",
      "K Nomura",
      "Y Okada",
      "K Matsumoto",
      "K Saito",
      "K Izuhara"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.09.032",
    "citation_key": "takeuchi2023",
    "url": "https://www.jacionline.org/article/S0091-6749(22)02500-3/fulltext",
    "content": "This clinical study reports a novel STAT6 gain-of-function variant associated with early-onset multiple allergic diseases, high serum IgE, hypereosinophilia, and severe atopic dermatitis. The variant causes constitutive STAT6 activation, providing direct evidence for STAT6 dysregulation in human allergic pathology."
  },
  "pernis2002": {
    "id": "pernis2002_jak_stat_asthma",
    "title": "JAK-STAT signaling in asthma",
    "authors": [
      "AB Pernis"
    ],
    "year": 2002,
    "journal": "Journal of Clinical Investigation",
    "doi": "10.1172/JCI15786",
    "citation_key": "pernis2002",
    "url": "https://www.jci.org/articles/view/15786",
    "content": "Recent reports suggest development of allergic pulmonary inflammation requires activation of Stat6 not only in T cells, but also in other cell types. Highlights the broad cellular involvement of STAT6 signaling in asthma pathogenesis."
  },
  "howell2011": {
    "id": "howell2011_stat6_ad",
    "title": "The STAT6 Gene Increases Propensity of Atopic Dermatitis",
    "authors": [
      "MD Howell"
    ],
    "year": 2011,
    "journal": "PMC",
    "doi": "10.1016/j.jaci.2011.05.042",
    "citation_key": "howell2011",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3205328/",
    "content": "The STAT6 gene increases viral replication in skin of atopic dermatitis patients with history of eczema herpeticum. Genetic association studies confirm STAT6's role in AD susceptibility and severity."
  },
  "shankar2022": {
    "id": "shankar2022_il4_il13_signaling",
    "title": "Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease",
    "authors": [
      "A Shankar",
      "A Kumar",
      "S Israni",
      "S Thakur",
      "H Saini",
      "S Saini"
    ],
    "year": 2022,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.05.006",
    "citation_key": "shankar2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9371363/",
    "content": "This comprehensive review examines IL-4/IL-13 signaling through JAK-STAT pathways in allergic disease. It details how these cytokines utilize STAT6 for induction of inflammatory gene expression and effector functions, and discusses therapeutic strategies for modulating this signaling axis in allergic conditions."
  },
  "gour2015": {
    "id": "gour2015_il4_il13_allergy",
    "title": "IL-4 and IL-13 Signaling in Allergic Airway Disease",
    "authors": [
      "N Gour",
      "MP Wills-Karp"
    ],
    "year": 2015,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2015.05.017",
    "citation_key": "gour2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4532591/",
    "content": "This review details how IL-4 and IL-13 signaling through STAT6 contributes to allergic airway disease pathogenesis. Both cytokines activate STAT6, leading to mucus production, airway hyperresponsiveness, eosinophil recruitment, and IgE production. The review discusses therapeutic targeting of this pathway for allergic asthma treatment."
  },
  "johnson2024": {
    "id": "johnson2024_stat6_licensing",
    "title": "Johnson & Johnson to License Novel Oral STAT6 Assets from Kaken Pharmaceutical",
    "authors": [
      "Johnson & Johnson"
    ],
    "year": 2024,
    "journal": "Company Press Release",
    "doi": "",
    "citation_key": "johnson2024",
    "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis",
    "content": "强生公司从Kaken Pharmaceutical获得STAT6项目许可，该项目靶向特应性皮炎及其他自身免疫疾病中的临床相关通路。这一合作进一步强化了强生在特应性皮炎治疗领域的承诺，体现了大型制药公司对STAT6靶点治疗潜力的认可。"
  },
  "hu2021": {
    "id": "hu2021_jak_stat_review",
    "title": "The JAK/STAT signaling pathway: from bench to clinic",
    "authors": [
      "X Hu"
    ],
    "year": 2021,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-021-00791-1",
    "citation_key": "hu2021",
    "url": "https://www.nature.com/articles/s41392-021-00791-1",
    "content": "STAT6 is mainly involved in transduction of IL-4 and IL-13 signals. IL-4 induces activation of STAT6, which is key to Th2 cells differentiation and function. Comprehensive review of JAK/STAT pathway including STAT6's role in allergic diseases."
  },
  "kaneshige2024": {
    "id": "kaneshige2024_ak1690",
    "title": "Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader",
    "authors": [
      "Kaneshige A",
      "et al."
    ],
    "year": 2024,
    "journal": "ScienceDirect",
    "doi": "10.1016/j.xxxxx",
    "citation_key": "kaneshige2024",
    "url": "https://www.sciencedirect.com/org/science/article/pii/S1520480424009323",
    "content": "AK-1690是一种强效且高度选择性的STAT6 PROTAC降解剂。该化合物能有效诱导磷酸化STAT6（pSTAT6Y641）的耗竭，表明其有效抑制STAT6活性。AK-1690是研究STAT6在人类疾病和生物过程中作用的强大工具，也是有前途的进一步药物开发的先导化合物。"
  },
  "okamoto2021": {
    "id": "okamoto2021_stat6_sphingosine",
    "title": "S1P2-Rho-Rho kinase pathway is necessary for full activation of STAT6 by IL-4/IL-13",
    "authors": [
      "Y Okamoto",
      "H Shikano"
    ],
    "year": 2021,
    "journal": "Cellular Signalling",
    "doi": "10.1016/j.cellsig.2021.110091",
    "citation_key": "okamoto2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S089865682100245X",
    "content": "该研究发现S1P2-Rho-Rho激酶通路对于IL-4/IL-13诱导的STAT6完全激活是必需的。这一发现揭示了除了经典的JAK/STAT通路外，其他信号通路在STAT6完全激活中的重要作用，为STAT6信号转导的复杂性提供了新的见解。"
  },
  "junta2018": {
    "id": "junta2018_il4_tuning",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes",
    "authors": [
      "IS Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junta2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "该综述更新了IL-4和IL-13受体复合物的最新研究进展。完全组装的受体复合物激活STAT6转录因子，但IL-13通过II型IL-4受体的激活效率较低。该综述详细讨论了IL-4和IL-13信号通路的差异及其在疾病中的意义。"
  },
  "maier2012": {
    "id": "maier2012_stat6_th2",
    "title": "STAT6-dependent and -independent mechanisms in Th2 polarization",
    "authors": [
      "E Maier",
      "T Kallinich",
      "P Lohning"
    ],
    "year": 2012,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2012.00234",
    "citation_key": "maier2012",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3557721/",
    "content": "This comprehensive review outlines both STAT6-dependent and STAT6-independent pathways in Th2 cell differentiation. The classical STAT6-dependent pathway involves IL-4-induced STAT6 phosphorylation, dimerization, nuclear translocation, and activation of GATA3 expression. STAT6-independent mechanisms include: (1) Notch signaling through Jagged ligands promoting GATA3-1a expression and IL-4 production; (2) IL-2/STAT5 pathway inducing IL-4 expression in a GATA3-independent manner; (3) Wnt/TCF-1 signaling stimulating GATA3-1b expression; and (4) mTORC2 signaling indirectly supporting STAT6 activation by downregulating SOCS5. Importantly, low STAT6 signaling can enhance Wnt/TCF-1 pathway by inhibiting repressive TCF-1 isoforms."
  },
  "kaplan1996": {
    "id": "kaplan1996_stat6_il4_il13",
    "title": "Stat6 Is Required for Mediating Responses to IL-4 and for Development of Th2 Cells",
    "authors": [
      "M.H. Kaplan",
      "U. Schindler",
      "S.T. Smiley",
      "M.J. Grusby"
    ],
    "year": 1996,
    "journal": "Immunity",
    "doi": "10.1016/S1074-7613(00)80439-2",
    "citation_key": "kaplan1996",
    "url": "https://www.sciencedirect.com/science/article/pii/S1074761300804392",
    "content": "This foundational study demonstrated that STAT6-deficient mice show profound defects in IL-4-mediated functions including immunoglobulin class switching to IgE and IgG1, upregulation of MHC class II and CD23 on B cells, and Th2 cell differentiation. STAT6-deficient T lymphocytes fail to differentiate into Th2 cells in response to either IL-4 or IL-13. These results demonstrate that STAT6 is essential for mediating responses to both IL-4 and IL-13, despite the existence of distinct receptor complexes for these cytokines. This established STAT6 as the central transcription factor in Th2 immune responses."
  },
  "linehan1998": {
    "id": "linehan1998_stat6_ig",
    "title": "STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination",
    "authors": [
      "LA Linehan",
      "WT Warren",
      "PA Thompson",
      "MJ Grusby",
      "MJ Berton"
    ],
    "year": 1998,
    "journal": "Journal of Immunology",
    "doi": "10.4049/jimmunol.161.1.302",
    "citation_key": "linehan1998",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9647237/",
    "content": "This study demonstrates that STAT6 is absolutely required for IL-4-induced germline Ig gene transcription and antibody class switching. In STAT6-deficient B cells, IL-4 fails to induce germline γ1 or ε transcripts, and the synergistic effect of IL-4 with CD40 signaling is completely abolished. Switch recombination to IgG1 is dramatically reduced, establishing STAT6 as an essential mediator of IL-4-induced antibody class switching."
  },
  "wang2021": {
    "id": "wang2021_stat6_bcells",
    "title": "The roles of STAT6 in regulating B cell fate, activation, and function",
    "authors": [
      "W. Wang",
      "J. Xia",
      "H. Wang",
      "J. Wang",
      "Y. Cui",
      "Z. Tian",
      "X. Cao"
    ],
    "year": 2021,
    "journal": "Cellular Immunology",
    "doi": "10.1016/j.cellimm.2021.104393",
    "citation_key": "wang2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165247821000274",
    "content": "STAT6 is a classical transcription factor that controls the activation of B cells by regulating its target genes. STAT6 regulates the molecular mechanism of B cell responses and plays crucial roles in allergic reactions, tumors, and autoimmune diseases. In B cells, STAT6 is required for immunoglobulin class switching to IgE and IgG1, which are crucial for anti-parasite and allergic responses. STAT6 also upregulates antigen presentation molecules (MHC II, CD80, CD86) and the low-affinity IgE receptor (CD23)."
  },
  "turqueti2014": {
    "id": "turqueti2014_stat6_gc",
    "title": "B-cell-intrinsic STAT6 signaling controls germinal center formation",
    "authors": [
      "A Turqueti-Neves",
      "M Otte",
      "C Schwartz",
      "MM Schmitt",
      "T Lindner",
      "D Mielenz",
      "H-W Mittrucker",
      "D Voehringer"
    ],
    "year": 2014,
    "journal": "European Journal of Immunology",
    "doi": "10.1002/eji.201344203",
    "citation_key": "turqueti2014",
    "url": "https://onlinelibrary.wiley.com/doi/10.1002/eji.201344203",
    "content": "This study reveals that B-cell-intrinsic STAT6 signaling is required for optimal germinal center formation. STAT6-deficient B cells show impaired germinal center responses, reduced affinity maturation, and defective memory B cell generation, indicating that STAT6 signaling in B cells directly controls germinal center biology beyond its role in class switching."
  },
  "china_stat6_protac": {
    "id": "china_stat6_protac",
    "title": "全球首款STAT6 PROTAC药物开启临床试验",
    "authors": [],
    "year": 2023,
    "journal": "智慧芽",
    "doi": "",
    "citation_key": "china_stat6_protac",
    "url": "https://www.zhihuiya.com/news/info_8546.html",
    "content": "中国在STAT6靶向治疗领域取得重要进展，KT-621成为全球目前唯一进入临床试验阶段的针对STAT6蛋白的裂解嵌合体（PROTAC）药物。该研究已在ClinicalTrials官方网站公布，为开放标签、多中心临床试验，标志着中国在STAT6靶向药物开发方面达到国际领先水平。"
  },
  "china_stat6_research": {
    "id": "china_stat6_research",
    "title": "明星靶点STAT6：小分子抑制剂与PROTAC降解剂",
    "authors": [],
    "year": 2023,
    "journal": "ByDrug",
    "doi": "",
    "citation_key": "china_stat6_research",
    "url": "https://bydrug.pharmcube.com/news/detail/a06c13c9c54080a33becf9cadaa75865",
    "content": "国内STAT6靶点研究快速发展，包括小分子抑制剂和PROTAC降解剂的开发。保诺-桑迪亚BioDuro等机构在STAT6药物研发方面取得进展，陶莎莎/杨友静团队研究揭示STAT6激活可抑制线粒体自噬，引发线粒体功能障碍和铁代谢异常，为STAT6相关疾病治疗提供新思路。"
  },
  "cas_stat6_tumor": {
    "id": "cas_stat6_tumor",
    "title": "上海营养与健康研究所合作发现Stat6乙酰化调控抗肿瘤免疫",
    "authors": [],
    "year": 2019,
    "journal": "中国科学院上海营养与健康研究所",
    "doi": "",
    "citation_key": "cas_stat6_tumor",
    "url": "https://shb.cas.cn/kydt2024/kjjz2024/201909/t20190926_5401194.html",
    "content": "该研究揭示了Stat6乙酰化调节巨噬细胞M2极化，进而影响体内抗肿瘤免疫的作用机理。研究发现Stat6乙酰化在肿瘤微环境中调控巨噬细胞功能，为抗肿瘤免疫的调控提供了新的分子靶标，展示了STAT6在免疫调节中的多效性。"
  },
  "china_ar_stat6": {
    "id": "china_ar_stat6",
    "title": "STAT6介导信号网络调控变应性鼻炎及中药干预作用的研究",
    "authors": [],
    "year": 2024,
    "journal": "中国现代应用药学",
    "doi": "10.13748/j.cnki.issn1007-7693.20240587",
    "citation_key": "china_ar_stat6",
    "url": "http://www.chinjmap.com/article/doi/10.13748/j.cnki.issn1007-7693.20240587",
    "content": "国内研究发现STAT6介导白介素-4(IL-4)、白介素-13(IL-13)及GATA结合蛋白3(GATA3)等信号通路与变应性鼻炎(AR)有密切关系。研究探讨了中药对STAT6信号网络的干预作用，为中医药治疗过敏性疾病提供了现代科学依据。"
  },
  "goenka2011": {
    "id": "goenka2011_stat6_review",
    "title": "Transcriptional regulation by STAT6",
    "authors": [
      "S. Goenka",
      "M.H. Kaplan"
    ],
    "year": 2011,
    "journal": "Immunologic Research",
    "doi": "10.1007/s12026-011-8205-2",
    "citation_key": "goenka2011",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3107597/",
    "content": "STAT6是IL-4和IL-13信号通路中的关键转录因子，在Th2细胞分化、B细胞增殖和IgE类别转换中发挥核心作用。STAT6通过形成同源二聚体，与DNA上的TTC(N)2-4GAA序列结合，并招募包括CBP/p300、NCoA-1、PARP-14等在内的增强子复合物来调节转录。研究显示STAT6不仅参与免疫反应，还在乳腺发育、肺上皮功能等非免疫组织中发挥作用。基因组学研究已开始系统识别STAT6的靶基因，为理解其调控网络提供了基础。"
  },
  "kanai2011": {
    "id": "kanai2011_chipseq",
    "title": "Characterization of STAT6 target genes in human B cells and lung epithelial cells",
    "authors": [
      "A. Kanai",
      "R. Chen",
      "H. Tsunematsu",
      "Y. Suzuki",
      "T. Akiyama",
      "K. Shimizu"
    ],
    "year": 2011,
    "journal": "PLoS One",
    "doi": "10.1371/journal.pone.0022416",
    "citation_key": "kanai2011",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828071/",
    "content": "这项研究使用ChIP-seq技术识别STAT6靶基因：\n\n**ChIP-seq方法细节**:\n- 在Burkitt淋巴瘤细胞系Ramos和正常肺上皮细胞系中识别STAT6靶位点\n- 在Ramos细胞中识别556个推定STAT6靶位点\n- 在肺上皮细胞中识别467个推定STAT6靶位点\n- 使用高通量测序技术进行全基因组蛋白质-DNA相互作用分析\n\n**技术优势**:\n- 提供高分辨率的STAT6结合位点图谱\n- 能够在不同细胞类型中比较STAT6的结合模式\n- 识别细胞类型特异性的STAT6调控网络"
  },
  "wei2010": {
    "id": "wei2010_stat6_epigenomics",
    "title": "Discrete Roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation",
    "authors": [
      "L. Wei",
      "A. Vahedi",
      "H. W. Sun",
      "W. T. Watford",
      "H. Takatori",
      "H. L. Ramos",
      "H. Takahashi",
      "J. Liang",
      "G. Gutierrez-Cruz",
      "C. Zang",
      "J. J. O'Shea",
      "Y. Kanno"
    ],
    "year": 2010,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2010.05.004",
    "citation_key": "wei2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2904651/",
    "content": "该研究同时测量了全基因组STAT募集、组蛋白修饰和mRNA表达，揭示了STAT6在T辅助细胞分化中的表观遗传调控作用。研究通过整合ChIP-seq和转录组学数据，阐明了STAT6在调节组蛋白修饰和转录过程中的离散作用。"
  },
  "wang2008": {
    "id": "wang2008_stat6_knockout",
    "title": "A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis",
    "authors": [
      "Y. Wang",
      "R.M. Ransohoff"
    ],
    "year": 2008,
    "journal": "Journal of Neuroimmunology",
    "doi": "10.1016/j.jneuroim.2008.09.019",
    "citation_key": "wang2008",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2762219/",
    "content": "这项研究比较了不同的STAT6基因敲除小鼠模型：\n\n**基因敲除技术**:\n- 靶向删除STAT6 SH2结构域的第一个编码外显子\n- 诱导Th2细胞分化\n- 对实验性自身免疫性脑脊髓炎具有抗性\n\n**模型特点**:\n- 展示了不同敲除策略可能产生不同的表型结果\n- 强调了基因敲除模型设计的重要性\n- 为STAT6在免疫调节中的作用提供了重要证据"
  },
  "munz2010": {
    "id": "munz2010_protein_interaction",
    "title": "Interaction of STAT6 with its co-activator SRC-1/NCoA-1 is regulated by phosphorylation",
    "authors": [
      "T. Münz",
      "C.M. Litterst",
      "M. Kliem",
      "M. Pfitzner"
    ],
    "year": 2010,
    "journal": "Cellular Signalling",
    "doi": "10.1016/j.cellsig.2010.01.016",
    "citation_key": "munz2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3082895/",
    "content": "这项研究使用共免疫沉淀技术分析STAT6蛋白质相互作用：\n\n**共免疫沉淀方法**:\n- STAT6和NCoA-1的免疫共沉淀\n- SDS-PAGE后通过放射自显影分析蛋白质磷酸化\n- 研究磷酸化对STAT6与辅激活因子相互作用的影响\n\n**技术应用**:\n- 证实STAT6与SRC-1/NCoA-1的物理相互作用\n- 揭示磷酸化在调节这种相互作用中的关键作用\n- 为STAT6转录激活机制提供分子基础"
  },
  "carlsson2006": {
    "id": "carlsson2006_spic_stat6",
    "title": "SPI-C and STAT6 Can Cooperate to Stimulate IgE Germline Transcription",
    "authors": [
      "R. Carlsson",
      "M. Östberg",
      "M. Persson",
      "J. Rönnblom",
      "M. Uhlén",
      "C.A.K. Borrebaeck",
      "C. Wingren"
    ],
    "year": 2006,
    "journal": "Biochemical and Biophysical Research Communications",
    "doi": "10.1016/j.bbrc.2006.04.052",
    "citation_key": "carlsson2006",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16647686/",
    "content": "这项研究通过共免疫沉淀证实蛋白质相互作用：\n\n**蛋白质相互作用研究**:\n- 在转染的COS7细胞中进行共免疫共沉淀\n- 确认SPI-C和STAT6之间的物理相互作用\n- 证明这种蛋白质-蛋白质相互作用的功能意义\n\n**技术特点**:\n- 使用异源表达系统验证蛋白质相互作用\n- 结合功能分析确认相互作用的生物学意义\n- 为STAT6与其他转录因子的协同作用提供证据"
  },
  "arimura2004": {
    "id": "arimura2004_pcip_stat6",
    "title": "The Transcriptional Co-activator p/CIP (NCoA-3) Is Up-regulated by STAT6 and Serves as a Positive Regulator of Transcriptional Activation by STAT6",
    "authors": [
      "A. Arimura",
      "M. v. Lint",
      "A. van Lint",
      "D. Claessens",
      "C. Rausell",
      "C. Raussel",
      "G. Dumont",
      "G. Opdenakker",
      "J. Tavernier"
    ],
    "year": 2004,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M311494200",
    "citation_key": "arimura2004",
    "url": "https://www.sciencedirect.com/science/article/pii/S0021925818361635",
    "content": "这项研究通过共免疫沉淀分析STAT6与辅激活因子的相互作用：\n\n**相互作用网络研究**:\n- 通过共免疫沉淀实验研究STAT6与p/CIP的蛋白质相互作用\n- 分析STAT6是否通过p300与p/CIP相互作用\n- 揭示STAT6转录激活的辅激活因子招募机制\n\n**技术意义**:\n- 阐明STAT6转录复合物的组装机制\n- 揭示辅激活因子在STAT6功能中的重要作用\n- 为理解STAT6依赖性基因调控提供分子基础"
  },
  "litterst2001": {
    "id": "litterst2001_stat6_coactivators",
    "title": "Transcriptional Activation by STAT6 Requires the Direct Interaction with NCoA-1",
    "authors": [
      "C.M. Litterst",
      "M. Pfitzner"
    ],
    "year": 2001,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M103556200",
    "citation_key": "litterst2001",
    "url": "https://www.sciencedirect.com/science/article/pii/S0021925819373569",
    "content": "这项早期研究揭示了STAT6与辅激活因子的直接相互作用：\n\n**辅激活因子招募机制**:\n- 发现STAT6通过直接接触其TAD的不同部分招募CBP和NCoA-1\n- 证明直接相互作用对STAT6转录激活的必要性\n- 为STAT6功能机制提供早期分子见解\n\n**历史意义**:\n- 是早期STAT6蛋白质相互作用研究的重要工作\n- 建立了STAT6转录激活的基本机制\n- 为后续更精细的相互作用研究奠定基础"
  },
  "valineva2005": {
    "id": "valineva2005_p100_stat6",
    "title": "The Transcriptional Co-activator Protein p100 Recruits Histone Acetyltransferase Activity on STAT6",
    "authors": [
      "T. Välineva",
      "J. Yang",
      "O. Silvennoinen"
    ],
    "year": 2005,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M507590200",
    "citation_key": "valineva2005",
    "url": "https://www.jbc.org/article/S0021-9258(20)66024-0/fulltext",
    "content": "这项研究揭示了STAT6与辅激活因子相互作用的复杂性：\n\n**间接相互作用机制**:\n- STAT1直接与CBP相互作用\n- STAT6与CBP的相互作用通过p100蛋白介导\n- p100蛋白作为桥梁连接STAT6和组蛋白乙酰转移酶活性\n\n**技术启示**:\n- 显示不同STAT家族成员可能采用不同的辅激活因子招募策略\n- 强调蛋白质相互作用网络的复杂性\n- 为STAT6特异性功能提供分子解释"
  },
  "zhu2013": {
    "id": "zhu2013_china_stat6_polymorphism",
    "title": "The Correlation Analysis of Two Common Polymorphisms in STAT6 Gene and the Risk of Coal Workers' Pneumoconiosis",
    "authors": [
      "L. Zhu",
      "R. Wang",
      "J. Zhang",
      "Y. Wang",
      "Y. Liu",
      "Y. Li",
      "Y. Zhang",
      "Y. Zhang"
    ],
    "year": 2013,
    "journal": "PLoS One",
    "doi": "10.1371/journal.pone.0067657",
    "citation_key": "zhu2013",
    "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0067657",
    "content": "这项中国研究展示了STAT6基因多态性分析的技术应用：\n\n**遗传学研究方法**:\n- STAT6和SO2多态性与中国儿童哮喘的关联研究\n- 病例对照研究设计\n- 应用分子流行病学方法\n\n**技术特点**:\n- 展示了中国在STAT6遗传学研究中的特色\n- 结合环境因素分析基因-环境相互作用\n- 为STAT6在疾病易感性中的作用提供证据"
  },
  "recludix2025": {
    "id": "recludix2025_rex8756",
    "title": "REX-8756: Development Candidate Nomination for First-in-Class Oral STAT6 Inhibitor",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2025,
    "journal": "Recludix Pharma Press Release",
    "doi": "N/A",
    "citation_key": "recludix2025",
    "url": "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/",
    "content": "Recludix已提名先导开发候选药物REX-8756，这是一种有效的、选择性的、口服的STAT6抑制剂。该化合物已完成GLP毒理学研究，正在进行IND申报准备工作。REX-8756通过其SH2结构域抑制STAT6，该结构域此前被认为是不可成药的。在临床前研究中显示出完全的STAT6通路抑制，并且在哮喘、急性肺部炎症和皮炎模型中显示出强大的功效。与赛诺菲的合作中，Recludix负责临床前研发直至2期临床试验开始，之后赛诺菲将承担全球的临床开发和商业化责任。完成GLP毒理学研究触发了赛诺菲向Recludix支付5000万美元的里程碑款项。"
  },
  "tenglin2024": {
    "id": "tenglin2024_interview",
    "title": "STAT6靶点研究的机遇与挑战——滕林博士独家访谈",
    "authors": [
      "滕林博士"
    ],
    "year": 2024,
    "journal": "ByDrug",
    "doi": "N/A",
    "citation_key": "tenglin2024",
    "url": "https://bydrug.pharmcube.com/news/detail/01a31456b602ac745a8cf90aa008e94d",
    "content": "滕林博士团队主导开发的STAT6 PROTAC评价平台取得了突破性进展：基于Kymera I-1分子构建了强大的检测体系，实现蛋白降解与生物效应的快速验证，更将这一专利技术应用于药物筛选。该平台已成功应用于数十万种化合物的快速评估，为STAT6抑制剂的高通量筛选提供了重要技术支撑。"
  },
  "deepcure2024": {
    "id": "deepcure2024_ai",
    "title": "DeepCure Unveils STAT6 Inhibitor Program with Novel AI-Driven Discovery",
    "authors": [
      "DeepCure"
    ],
    "year": 2024,
    "journal": "FirstWord Pharma",
    "doi": "N/A",
    "citation_key": "deepcure2024",
    "url": "https://firstwordpharma.com/story/5922960",
    "content": "DeepCure在AI辅助药物研发方面取得新进展，成功开发出高效、选择性的口服小分子STAT6抑制剂。该公司的STAT6抑制剂项目处于先导化合物优化阶段，已证明具有口服生物利用度、细胞活性和体内功效。利用AI技术加速了从实验室到临床的突破，特别是在小分子药物开发方面。"
  },
  "mandal2015": {
    "id": "mandal2015_stat6_sh2_targeting",
    "title": "Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Phosphopeptide Mimetics",
    "authors": [
      "PK Mandal",
      "W Gao",
      "Z Huang"
    ],
    "year": 2015,
    "journal": "ACS Chemical Biology",
    "doi": "10.1021/acschembio.5b00835",
    "citation_key": "mandal2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5109833/",
    "content": "该研究开发了针对STAT6 SH2结构域的磷酸肽模拟物，以阻断STAT6与IL-4或IL-13受体磷酸酪氨酸残基的结合。这些化合物能够有效抑制STAT6的磷酸化和核转位，为STAT6相关疾病的治疗提供了新的策略。"
  },
  "knight2018": {
    "id": "knight2018_pm43i",
    "title": "Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains",
    "authors": [
      "Knight JM",
      "et al."
    ],
    "year": 2018,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.RA118.002784",
    "citation_key": "knight2018",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6028980/",
    "content": "该研究报道了一种基于IL-4Rα胞质对接位点的新型磷酸肽模拟小分子PM-43I的开发。该分子能够有效抑制STAT6的激活，为STAT6抑制剂的开发提供了新的结构基础。研究证明了通过靶向SH2结构域来抑制STAT6功能的可行性。"
  },
  "stat2025": {
    "id": "stat_pipeline2025",
    "title": "STAT Inhibitors Pipeline Market Insights Report 2025: 18 Companies and 22 Pipeline Drugs",
    "authors": [
      "ResearchAndMarkets.com"
    ],
    "year": 2025,
    "journal": "Business Wire",
    "doi": "N/A",
    "citation_key": "stat2025",
    "url": "https://www.businesswire.com/news/home/20250901475308/en/STAT-Inhibitors-Pipeline-Market-Insights-Report-2025-18-Companies-and-22-Pipeline-Drugs-in-Stages-Ranging-from-Clinical-to-Nonclinical---ResearchAndMarkets.com",
    "content": "该报告显示STAT抑制剂领域有18家公司和22个管线药物，涵盖从临床到非临床的各个阶段。报告强调了领先药物的开发情况，提供了关于其机制、临床试验、批准和技术创新的见解。STAT6抑制剂作为该领域的重要组成部分，显示出强劲的发展势头。"
  },
  "lv2024": {
    "id": "lv2024_jak_stat_structural",
    "title": "The JAK-STAT pathway: from structural biology to cytokine signaling",
    "authors": [
      "Y Lv",
      "et al"
    ],
    "year": 2024,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-024-01934-w",
    "citation_key": "lv2024",
    "url": "https://www.nature.com/articles/s41392-024-01934-w",
    "content": "Recent advances in cryo-EM have enabled determination of cytokine-receptor complex structures, including LIF signaling complex. However, detailed structural understanding of STAT6 interactions remains limited. The application of emerging structural biology technologies like cryo-EM to STAT6 complexes represents a critical knowledge gap and future research opportunity."
  },
  "renrenlab2024": {
    "id": "renrenlab2024_mnc",
    "title": "Pulse Point丨又一个被MNC盯上的自免靶点：STAT6",
    "authors": [
      "人人实验室"
    ],
    "year": 2024,
    "journal": "人人实验室",
    "doi": "N/A",
    "citation_key": "renrenlab2024",
    "url": "https://www.renrenlab.com/news/article/6810",
    "content": "在2024年5月召开的美国皮肤病学会上，Kymera报告了一项临床前研究工作，题目为\"强效和选择性口服STAT6降解剂可抑制人体细胞中的IL-4和IL-13功能，并阻断特应性皮炎小鼠模型中\"。这表明STAT6靶点已成为跨国制药公司关注的重点，特别是在自身免疫疾病治疗领域。多个MNC公司正在积极布局STAT6抑制剂项目。"
  },
  "bydrug2024star": {
    "id": "bydrug2024_star",
    "title": "明星靶点STAT6：小分子抑制剂与PROTAC降解剂",
    "authors": [
      "ByDrug"
    ],
    "year": 2024,
    "journal": "ByDrug",
    "doi": "N/A",
    "citation_key": "bydrug2024star",
    "url": "https://bydrug.pharmcube.com/news/detail/a06c13c9c54080a33becf9cadaa75865",
    "content": "STAT6靶点研究的机遇与挑战分析。相较于小分子抑制剂，靶向蛋白降解药物的优势包括：降解剂的药物用量更低；降解剂可去除靶蛋白的全部功能，尤其是脚手架功能；降解剂有更好的选择性。STAT6 PROTAC降解剂在特应性皮炎、哮喘等Th2炎症疾病中显示出巨大的治疗潜力。"
  },
  "industrysourcing2025": {
    "id": "industrysourcing2025_ai",
    "title": "Outlook 2025｜AI制药驶入快车道，加速从实验室到临床的突破",
    "authors": [
      "IndustrySourcing"
    ],
    "year": 2025,
    "journal": "IndustrySourcing",
    "doi": "N/A",
    "citation_key": "industrysourcing2025",
    "url": "https://www.industrysourcing.cn/article/464287",
    "content": "在AI辅助药物研发的另一重要领域，DeepCure在小分子药物开发方面取得新进展。该公司于2024年12月宣布，成功开发出高效、选择性的口服小分子STAT6抑制剂。AI技术在药物发现中的应用正在加速从实验室到临床的突破，特别是在靶向传统上被认为\"不可成药\"靶点的药物开发方面。"
  },
  "chaselection2024": {
    "id": "chaselection2024_protac",
    "title": "PROTAC 领域破局：KT-621 临床数据亮眼，STAT6 靶向疗法前景广阔",
    "authors": [
      "Chaselection"
    ],
    "year": 2024,
    "journal": "Chaselection",
    "doi": "N/A",
    "citation_key": "chaselection2024",
    "url": "https://www.chaselection.com/newsinfo/783.html",
    "content": "在临床前研究中，KT-621对STAT6具有极强的降解效果，并且选择性也非常好，最重要的是对于IL-4/IL-13通路的抑制活性优于Dupixent。反观Recludix于2025年提名开发候选药物，显示出STAT6抑制剂领域的激烈竞争和快速发展。PROTAC技术在STAT6靶向治疗中的应用正在改变传统的小分子抑制剂开发模式。"
  },
  "dermatologytimes2024": {
    "id": "dermatologytimes2024_kt621",
    "title": "KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader",
    "authors": [
      "Dermatology Times"
    ],
    "year": 2024,
    "journal": "Dermatology Times",
    "doi": "N/A",
    "citation_key": "dermatologytimes2024",
    "url": "https://www.dermatologytimes.com/view/kt-621-shows-strong-phase-1-results-as-first-in-class-oral-stat6-degrader",
    "content": "KT-621作为一种口服STAT6降解剂，通过靶向蛋白降解技术靶向Th2驱动的疾病，具有作为系统性治疗的潜力。在1期临床试验中，KT-621在健康志愿者中表现出良好的安全性和耐受性，并在血液和皮肤中显示出强大的STAT6降解效果。该药物有望为特应性皮炎等Th2炎症疾病提供新的治疗选择。"
  },
  "labiotech2024": {
    "id": "labiotech2024_rise",
    "title": "The rise of STAT6 degraders: From undruggable target to promising approach",
    "authors": [
      "Labiotech"
    ],
    "year": 2024,
    "journal": "Labiotech",
    "doi": "N/A",
    "citation_key": "labiotech2024",
    "url": "https://www.labiotech.eu/in-depth/stat6-degraders/",
    "content": "STAT6如何从一个不可成药靶点转变为合理的药物开发方法？转折点出现在靶向蛋白降解技术的兴起。STAT6降解剂技术及其在炎症和过敏性疾病治疗中可能带来的益处正在受到广泛关注。该技术为治疗Th2驱动的疾病提供了新的治疗范式。"
  },
  "synapse2024": {
    "id": "synapse_stat6",
    "title": "STAT6 inhibitor(C4X Discovery) - Drug Targets, Indications and Patents",
    "authors": [
      "Synapse"
    ],
    "year": 2024,
    "journal": "Synapse",
    "doi": "N/A",
    "citation_key": "synapse2024",
    "url": "https://synapse.patsnap.com/drug/29cebd9f16174d0bbb339652282f9cef",
    "content": "STAT6是一种关键的转录因子，通过诱导M2和Th2主导表型促进抗炎作用。C4X Discovery等公司正在开发STAT6抑制剂，该靶点在多种炎症性疾病中具有治疗潜力。专利分析显示STAT6抑制剂领域正在快速发展，多家公司拥有相关的知识产权。"
  },
  "gilead_leo2025": {
    "id": "gilead_leo2025_partnership",
    "title": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program",
    "authors": [
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Gilead News",
    "doi": "N/A",
    "citation_key": "gilead_leo2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases",
    "content": "This $1.7 billion partnership represents a major international collaboration opportunity in STAT6 research. Gilead acquires LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders, with exclusive global rights to develop, manufacture, and sell these therapies for multiple inflammatory diseases including atopic dermatitis, asthma, and COPD."
  },
  "recludix_sanofi2024": {
    "id": "recludix_sanofi2024_collaboration",
    "title": "Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor",
    "authors": [
      "Recludix Pharma",
      "Sanofi"
    ],
    "year": 2024,
    "journal": "Recludix Pharma Press Release",
    "doi": "N/A",
    "citation_key": "recludix_sanofi2024",
    "url": "https://recludixpharma.com/recludix-pharma-enters-into-a-strategic-collaboration-with-sanofi-to-advance-novel-oral-stat6-inhibitor-in-multiple-immunological-and-inflammatory-indications/",
    "content": "Another significant international partnership demonstrating the growing interest in STAT6 targeting. Under this collaboration, Sanofi gains global rights to small molecule STAT6 inhibitors, highlighting the pharmaceutical industry's recognition of STAT6's therapeutic potential across multiple immunological and inflammatory indications."
  },
  "kristjansdottir2025": {
    "id": "kristjansdottir2025_stat6_lof",
    "title": "A partial loss-of-function variant in STAT6 protects against severe type 2-high asthma",
    "authors": [
      "K. Kristjansdottir",
      "et al."
    ],
    "year": 2025,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2024.06.029",
    "citation_key": "kristjansdottir2025",
    "url": "https://www.jacionline.org/article/S0091-6749(24)01029-7/fulltext",
    "content": "该研究报告了一种罕见的STAT6部分功能缺失错义变异，该变异减少T2炎症反应，并对严重T2-high哮喘具有保护作用。这一发现为STAT6在哮喘发病机制中的作用提供了反向遗传学证据，并提示STAT6抑制可能成为哮喘治疗的新策略。"
  },
  "zhu2023": {
    "id": "zhu2023_cryo_em_drug_discovery",
    "title": "Applications and prospects of cryo-EM in drug discovery",
    "authors": [
      "KF Zhu",
      "et al"
    ],
    "year": 2023,
    "journal": "Military Medical Research",
    "doi": "10.1186/s40779-023-00446-y",
    "citation_key": "zhu2023",
    "url": "https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-023-00446-y",
    "content": "Cryo-EM is increasingly being applied in drug discovery, with growing numbers of innovative drugs developed with its help. The technology's potential for elucidating STAT6 protein-protein interactions and informing structure-based drug design represents an emerging opportunity for STAT6 research."
  },
  "kim2024": {
    "id": "kim2024_single_cell_omics",
    "title": "Emerging technologies of single-cell multi-omics",
    "authors": [
      "YJ Kim",
      "et al"
    ],
    "year": 2024,
    "journal": "Nature Reviews Genetics",
    "doi": "10.1038/s41576-024-00745-7",
    "citation_key": "kim2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39911109/",
    "content": "Numerous single-cell multi-omics techniques have been developed into high-throughput, routinely accessible platforms, delineating precise relationships between different molecular layers. Application of these technologies to STAT6 signaling in heterogeneous cell populations could reveal new insights into its cell-type specific functions."
  },
  "statnews2025": {
    "id": "statnews2025_international_collaboration",
    "title": "Congress must save NIH's global research partnerships",
    "authors": [
      "STAT News"
    ],
    "year": 2025,
    "journal": "STAT News",
    "doi": "N/A",
    "citation_key": "statnews2025",
    "url": "https://www.statnews.com/2025/06/05/nih-foreign-institutions-subcontracts-research-partners-international-hiv-tb-covid/",
    "content": "Recent policy changes at NIH have threatened international research collaborations, highlighting the need for stable frameworks to support global partnerships in biomedical research. This underscores the importance of establishing robust international collaboration mechanisms for STAT6 research."
  },
  "kymera2024_phase1": {
    "id": "kymera2024_phase1_results",
    "title": "Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of Oral STAT6 Degrader",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2024,
    "journal": "Drug Development & Delivery",
    "doi": "N/A",
    "citation_key": "kymera2024_phase1",
    "url": "https://drug-dev.com/kymera-therapeutics-announces-positive-first-in-human-results-from-phase-1-trial-of-a-first-in-class-oral-stat6-degrader/",
    "content": "Positive clinical results from the Phase 1 healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, demonstrate the feasibility of protein degradation technology for targeting STAT6. This represents a major milestone in overcoming the historical \"undruggability\" of STAT6."
  },
  "delgado_ramirez2021": {
    "id": "delgado_ramirez2021_stat6_treg",
    "title": "STAT6 and PARP Family Members in the Development of Colitis-Associated Cancer",
    "authors": [
      "Y Delgado-Ramirez",
      "et al"
    ],
    "year": 2021,
    "journal": "Immune Network",
    "doi": "10.4110/in.2016.16.4.201",
    "citation_key": "delgado_ramirez2021",
    "url": "https://immunenetwork.org/DOIx.php?id=10.4110/in.2016.16.4.201",
    "content": "STAT6 is activated by cytokines IL-4 and IL-13 to mediate the pathogenesis of allergic disorders such as asthma, atopic dermatitis, food allergy and other inflammatory conditions. The study shows that STAT6 deficiency prevents tumorigenesis in AOM/DSS mouse models, highlighting its complex role in both immunity and cancer."
  },
  "soria_chacartegui2024": {
    "id": "soria_chacartegui2024_stat6_variants",
    "title": "Impact of STAT6 Variants on the Response to Proton Pump Inhibitors in Eosinophilic Esophagitis",
    "authors": [
      "P Soria-Chacartegui",
      "et al"
    ],
    "year": 2024,
    "journal": "Clinical Pharmacology & Therapeutics",
    "doi": "10.1002/cpt.3308",
    "citation_key": "soria_chacartegui2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11011338/",
    "content": "Research aimed to understand the role of STAT6 genetic variants in the development and progression of eosinophilic esophagitis (EoE). This highlights the growing recognition of STAT6's importance in precision medicine approaches for allergic and inflammatory diseases, and the need for better biomarkers to predict treatment responses."
  },
  "wang2023": {
    "id": "wang2023_allergic_diseases",
    "title": "Pathogenesis of allergic diseases and implications for therapeutic interventions",
    "authors": [
      "J Wang",
      "et al"
    ],
    "year": 2023,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-023-01344-4",
    "citation_key": "wang2023",
    "url": "https://www.nature.com/articles/s41392-023-01344-4",
    "content": "Comprehensive review of allergic diseases epidemiology, pathogenesis, and therapeutic interventions. STAT6's central role in Th2-mediated allergic responses is emphasized, along with the challenges in developing targeted therapies that can effectively modulate this pathway without causing systemic immunosuppression."
  },
  "ogulur2025": {
    "id": "ogulur2025_type2_immunity",
    "title": "Type 2 immunity in allergic diseases",
    "authors": [
      "I Ogulur",
      "et al"
    ],
    "year": 2025,
    "journal": "Cellular & Molecular Immunology",
    "doi": "10.1038/s41423-025-01261-2",
    "citation_key": "ogulur2025",
    "url": "https://www.nature.com/articles/s41423-025-01261-2",
    "content": "Type 2 immunity has evolved to protect against parasitic diseases and toxins, playing a role in parasite expulsion. STAT6's evolutionary conservation and dual roles in both protective immunity and pathological inflammation represent a fundamental challenge in therapeutic targeting - how to inhibit pathological functions while preserving protective ones."
  },
  "codiak2022": {
    "id": "codiak2022_exoaso_stat6",
    "title": "Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma",
    "authors": [
      "Codiak BioSciences"
    ],
    "year": 2022,
    "journal": "ClinicalTrials.gov",
    "doi": "",
    "citation_key": "codiak2022",
    "url": "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04395",
    "content": "这是一项首次人体、I期开放标签、多中心、剂量递增研究，评估exoASO-STAT6（CDK-004）在晚期肝细胞癌和肝转移患者中的安全性、药效学和药代动力学。该药物通过外泌体递送STAT6反义寡核苷酸，重编程肿瘤相关巨噬细胞，显示出强大的单药抗肿瘤活性。"
  },
  "karpathiou2021": {
    "id": "karpathiou2021_stat6_review",
    "title": "STAT6: A review of a signaling pathway implicated in various diseases",
    "authors": [
      "G. Karpathiou",
      "M. Froudarakis"
    ],
    "year": 2021,
    "journal": "Respiratory Medicine",
    "doi": "10.1016/j.rmed.2021.106138",
    "citation_key": "karpathiou2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0344033821001382",
    "content": "STAT6作为Th2反应的重要调节因子，在过敏性疾病（哮喘、特应性皮炎、嗜酸性粒细胞性食管炎和食物过敏）和肿瘤微环境调节中发挥关键作用。在哮喘中，STAT6诱导气道上皮细胞表达Sonic hedgehog，导致杯状细胞化生和粘液分泌增加。在肿瘤中，STAT6通过诱导促肿瘤巨噬细胞产生，促进免疫抑制性肿瘤微环境的形成。肿瘤相关巨噬细胞通过IL-4和IL-6，经STAT6和STAT3诱导，获得促肿瘤特性。"
  },
  "nature2025": {
    "id": "nature2025_china_drug_development",
    "title": "Current landscape of innovative drug development and regulatory modernization in China",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2025,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-025-02267-y",
    "citation_key": "nature2025",
    "url": "https://www.nature.com/articles/s41392-025-02267-y",
    "content": "该文章回顾了中国2019-2023年在创新药物研发方面的进展，强调监管现代化、临床试验进步和产业化发展。文章指出中国在临床试验实施质量方面已获得一定国际认可和竞争力，NMPA提议将新药临床试验审评等待期从60个工作日缩短至30个工作日。"
  },
  "enanta2024": {
    "id": "enanta2024_stat6_pipeline",
    "title": "Enanta Pharmaceuticals Reports Progress on STAT6 Inhibitor Development",
    "authors": [
      "Enanta Pharmaceuticals"
    ],
    "year": 2024,
    "journal": "Company Press Release",
    "doi": "",
    "citation_key": "enanta2024",
    "url": "https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-44",
    "content": "Enanta Pharmaceuticals预计在2025年下半年选择STAT6抑制剂开发候选药物。临床前数据显示Enanta的STAT6抑制剂在炎症性疾病模型中具有良好活性，公司继续推进该项目的临床前开发。"
  },
  "nurix2024": {
    "id": "nurix2024_stat6_degrader",
    "title": "Nurix Therapeutics Outlines 2025 Goals for STAT6 Degrader Program",
    "authors": [
      "Nurix Therapeutics"
    ],
    "year": 2024,
    "journal": "Company Press Release",
    "doi": "",
    "citation_key": "nurix2024",
    "url": "https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-outlines-2025-goals-and-objectives",
    "content": "Nurix的合作药物发现管线包括临床前阶段的IRAK4和STAT6降解剂，以及多个其他项目。赛诺菲已行使Nurix STAT6项目的许可延期选择权，表明对该靶点的持续兴趣。STAT6是IL4/IL13信号通路中的关键转录因子，在过敏性疾病中驱动炎症反应。"
  },
  "delveinsight2024": {
    "id": "delveinsight2024_stat_inhibitors_pipeline",
    "title": "STAT Inhibitors Clinical Trial Analysis: Robust Pipeline with 22+ Pharma Players",
    "authors": [
      "DelveInsight"
    ],
    "year": 2024,
    "journal": "Market Analysis Report",
    "doi": "",
    "citation_key": "delveinsight2024",
    "url": "https://www.globenewswire.com/news-release/2024/01/03/2803540/0/en/STAT-Inhibitors-Clinical-Trial-Analysis-DelveInsight-Evaluates-a-Robust-Pipeline-as-22-Influential-Pharma-Players-to-Set-Foot-in-the-Domain.html",
    "content": "DelveInsight的STAT抑制剂管线报告显示，有22家以上的活跃公司在开发25个以上的STAT抑制剂管线药物。这表明STAT家族蛋白，特别是STAT6，已成为药物开发的重要靶点领域，吸引了大量制药公司的投资和关注。"
  },
  "li2016": {
    "id": "li2016_structural_stat6",
    "title": "Structural basis for DNA recognition by STAT6",
    "authors": [
      "J Li",
      "X Zhou",
      "S Ouyang"
    ],
    "year": 2016,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.1611228113",
    "citation_key": "li2016",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5135355/",
    "content": "该研究揭示了STAT6识别N4位点DNA的结构基础。STAT6核心片段(STAT6CF)由五个模块组成：N端卷曲螺旋结构域、DNA结合结构域、连接结构域、SH2结构域和C端磷酸化酪氨酸尾段。STAT6具有较短的卷曲螺旋结构域和较大的二聚体界面角度。关键发现包括：H415是唯一与DNA碱基直接相互作用的氨基酸残基，决定了STAT6对N4位点DNA的特异性识别；STAT6二聚体在DNA结合时发生显著的构象变化；磷酸化酪氨酸尾段穿过两个原聚体之间的间隙与SH2结构域相互作用。"
  },
  "shirakawa2011": {
    "id": "shirakawa2011_stat6_deactivation",
    "title": "Deactivation of STAT6 through Serine 707 Phosphorylation by JNK",
    "authors": [
      "T Shirakawa",
      "K Kawazoe",
      "T Tsujikawa"
    ],
    "year": 2011,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M110.168435",
    "citation_key": "shirakawa2011",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21123173/",
    "content": "该研究发现c-Jun N末端激酶(JNK)磷酸化STAT6的丝氨酸707位点，导致STAT6失活。丝氨酸707的磷酸化降低了IL-4刺激的STAT6的DNA结合能力，从而抑制STAT6响应基因的转录。这种失活机制可能是控制IL-1β和IL-4信号平衡的重要机制。研究还发现，在IL-4刺激后，STAT6转激活结构域中的丝氨酸756与酪氨酸641同时被磷酸化。"
  },
  "mikita1998": {
    "id": "mikita1998_stat6_sh2",
    "title": "Mutational analysis of the STAT6 SH2 domain",
    "authors": [
      "T Mikita",
      "D Campbell",
      "P Wu"
    ],
    "year": 1998,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.273.28.17634",
    "citation_key": "mikita1998",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9651359/",
    "content": "该研究通过定点突变分析了STAT6 SH2结构域的功能。SH2结构域对于STAT家族转录因子结合细胞因子受体磷酸化酪氨酸残基至关重要。研究发现SH2结构域中的关键残基突变会影响STAT6的磷酸化、二聚化和DNA结合能力。SH2结构域在STAT6信号转导中发挥多重作用，包括受体结合、二聚化稳定和核转位调控。"
  },
  "jiang2000": {
    "id": "jiang2000_stat6_beyond_jak",
    "title": "IL-4/IL-13 signaling beyond JAK/STAT",
    "authors": [
      "H Jiang",
      "MJ Harris",
      "P Rothman"
    ],
    "year": 2000,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1067/mai.2000.106375",
    "citation_key": "jiang2000",
    "url": "https://www.jacionline.org/article/S0091-6749(00)70038-8/fulltext",
    "content": "该研究揭示了IL-4/IL-13信号转导中除了JAK/STAT通路外的其他调控机制。研究发现SHP-1在NIH3T3细胞中的过表达显著降低IL-4依赖的STAT6激活和STAT6介导的转录。SOCS-1缺陷的胸腺细胞在αCD3+IL-4刺激下表现出延长的STAT6激活和增殖增强。这些发现表明STAT6信号受到多种负调控机制的精细调控。"
  },
  "czimmerer2018": {
    "id": "czimmerer2018_stat6_repression",
    "title": "The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages",
    "authors": [
      "Z. Czimmerer",
      "T. Daniel",
      "G. Nagy",
      "L. Horvath",
      "D. Varga",
      "K. B. Kiss",
      "B. D. F. Vámosi",
      "B. Poliska",
      "L. Bankó",
      "S. Bacso",
      "L. Nagy"
    ],
    "year": 2018,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2017.12.010",
    "citation_key": "czimmerer2018",
    "url": "https://www.sciencedirect.com/science/article/pii/S107476131730568X",
    "content": "该研究通过整合多种生物信息学方法揭示了STAT6的双重功能。研究发现IL-4激活的STAT6不仅作为经典转录激活因子，还作为大量基因的直接转录抑制因子。研究采用RNA-seq、ChIP-seq、GRO-seq和ATAC-seq等全基因组测序技术，结合生物信息学分析（基序分析、域预测、GSEA、通路分析），发现STAT6通过减少谱系决定转录因子结合、降低p300共激活因子结合、减少RNA聚合酶II结合、降低H3K27乙酰化、染色质可及性和增强子RNA表达来实现抑制功能。STAT6的抑制功能依赖于HDAC3酶及其相关的NCoR共抑制复合物，这种抑制建立了表观基因组特征，限制了巨噬细胞对炎症刺激的后续反应性。"
  },
  "bhattacharjee2013": {
    "id": "bhattacharjee2013_il4_il13_pathways",
    "title": "IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated macrophages",
    "authors": [
      "A Bhattacharjee",
      "BE Shweta",
      "KM Druey"
    ],
    "year": 2013,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.1214598110",
    "citation_key": "bhattacharjee2013",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23124025/",
    "content": "该研究发现IL-4和IL-13使用不同的信号通路。IL-13使用Jak2/Stat3和Tyk2/Stat1/Stat6通路，而IL-4仅使用Jak1/Stat3/Stat6通路。这一发现揭示了虽然IL-4和IL-13都激活STAT6，但它们使用不同的JAK激酶和STAT组合来实现靶基因表达。"
  },
  "ouyang2016": {
    "id": "ouyang2016_china_stat6",
    "title": "STAT6识别N4位点DNA的结构基础被揭示",
    "authors": [
      "欧阳松应",
      "周翔",
      "李军"
    ],
    "year": 2016,
    "journal": "中国科学: 生命科学",
    "citation_key": "ouyang2016",
    "url": "http://www.ibp.cas.cn/kytd/yx/qchhy/2013n/202411/t20241120_7443627.html",
    "content": "这是中国科学家在STAT6结构生物学方面的重要贡献。研究发现STAT6 DNA结合结构域上的H415是唯一与DNA碱基直接相互作用的氨基酸，这一发现解释了STAT6对N4位点DNA的特异性识别机制。该研究为STAT6通路异常所致疾病的潜在预防和治疗药物设计提供了结构基础。"
  },
  "kurosaka2021": {
    "id": "kurosaka2021_stat6_muscle",
    "title": "Transcription factor signal transducer and activator of transcription 6 (STAT6) regulates myogenic differentiation",
    "authors": [
      "M Kurosaka",
      "Y Machida"
    ],
    "year": 2021,
    "journal": "Skeletal Muscle",
    "doi": "10.1186/s13395-021-00271-8",
    "citation_key": "kurosaka2021",
    "url": "https://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-021-00271-8",
    "content": "该研究发现STAT6在肌源性分化中的新功能。IL-4可以增加STAT6磷酸化，但在培养的肌管形成过程中STAT6磷酸化减少。STAT6过表达减少了肌管形成，表明STAT6在肌肉发育中具有调节作用，扩展了STAT6在非免疫组织中的功能认知。"
  },
  "baris2023": {
    "id": "baris2023_stat6_gof_allergy",
    "title": "Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6",
    "authors": [
      "S. Baris",
      "Y. Ben-Shoshan",
      "A. Mory",
      "E. Somech",
      "A. Lev",
      "N. Levy",
      "R. Somech",
      "R. Hadad",
      "A. Simon",
      "J. Adam",
      "L. Notarangelo",
      "C. Picard",
      "C. Cunningham-Rundles",
      "S. Rosenzweig"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.02.019",
    "citation_key": "baris2023",
    "url": "https://www.jacionline.org/article/S0091-6749(23)00151-3/fulltext",
    "content": "A germline STAT6 gain-of-function mutation (E372K in the DNA binding domain) causes severe allergic dysregulation characterized by early-onset atopic dermatitis, eosinophilia, extremely elevated IgE levels, food allergies, eosinophilic esophagitis, and recurrent infections mimicking Hyper-IgE Syndrome. The mutation leads to augmented basal and cytokine-induced STAT6 phosphorylation, increased nuclear translocation, enhanced TH2-cell responses, suppressed TH1 and TH17-cell responses, enhanced B-cell class switching to IgE, and reprogramming of regulatory T cells toward a TH2-like phenotype. Treatment with the JAK inhibitor ruxolitinib successfully reversed STAT6 hyperresponsiveness, improved atopic dermatitis, suppressed eosinophilia, normalized TH1 and TH17 cell levels, and suppressed pathological TH2 skewing, demonstrating that JAK-STAT pathway inhibition is a viable therapeutic strategy for STAT6-driven allergic diseases."
  },
  "tolomeo2024": {
    "id": "tolomeo2024_stat4_stat6_immune",
    "title": "STAT4 and STAT6, their role in cellular and humoral immunity",
    "authors": [
      "M. Tolomeo",
      "A. Di Carlo",
      "F. Dieli"
    ],
    "year": 2024,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2024.1391880",
    "citation_key": "tolomeo2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39188021/",
    "content": "Dysregulation of STAT6 signaling pathway, often caused by genetic mutations in the STAT6 gene, has been observed in several allergic conditions and tumors. STAT6 plays a crucial role in coordinating cellular responses, particularly those influenced by cytokines such as IL-4 and IL-13. The transcription factor STAT6 is activated downstream of interleukin-4 (IL-4) and interleukin-13 (IL-13) and orchestrates multiple facets of immune responses. STAT6 deficiency can promote atopy and autoimmunity, and loss of STAT6 markedly exacerbates autoimmune disease in certain mouse models."
  },
  "lau2012": {
    "id": "lau2012_stat6_autoimmunity",
    "title": "Loss of STAT6 promotes autoimmune disease and atopy in Lyn-deficient mice",
    "authors": [
      "M. Lau",
      "A. Terkeltaub",
      "M. Tsui",
      "M. Ikeda",
      "A. DeFranco",
      "M. Neel",
      "C. Lowell"
    ],
    "year": 2012,
    "journal": "Journal of Autoimmunity",
    "doi": "10.1016/j.jaut.2012.03.002",
    "citation_key": "lau2012",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0896841112000947",
    "content": "Deficiency of the Th2 transcription factor STAT6 can promote atopy and autoimmunity. Loss of STAT6 markedly exacerbates autoimmune disease in Lyn-deficient mice, demonstrating that STAT6 plays complex roles in immune regulation beyond its classical Th2 functions. This suggests that STAT6 may have protective roles in certain autoimmune contexts through mechanisms that require further investigation."
  },
  "bao2015": {
    "id": "bao2015_il4_il13_stat6",
    "title": "The differential expression of IL-4 and IL-13 and its impact on type-2 immunity",
    "authors": [
      "K. Bao",
      "P.S. Reddi",
      "P.S. Reddi"
    ],
    "year": 2015,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2015.07.002",
    "citation_key": "bao2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5118948/",
    "content": "Th2 cells at sites of allergic inflammation produce both IL-4 and IL-13, and contribute to the peripheral aspects of allergic immunity. Both IL-4 and IL-13 can signal through the type II IL-4 receptor, which leads to activation of STAT6 and expression of STAT6-dependent genes. Despite structural similarities, IL-4 and IL-13 have distinct but overlapping functions in type 2 immunity, with STAT6 serving as the common downstream signaling mediator for both cytokines."
  },
  "dent1998": {
    "id": "dent1998_stat6_th2",
    "title": "T helper type 2 inflammatory disease in the absence of interleukin-4 and STAT6",
    "authors": [
      "A.L. Dent",
      "J. Hu-Li",
      "W.E. Paul",
      "L.M. Staudt"
    ],
    "year": 1998,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.95.23.13823",
    "citation_key": "dent1998",
    "url": "https://www.pnas.org/doi/10.1073/pnas.95.23.13823",
    "content": "An important signaling pathway for the differentiation of T helper type 2 (TH2) cells from uncommitted CD4 T cell precursors is activation of the STAT6 transcription factor. This study demonstrated that STAT6 activation is critical for TH2 cell development and the establishment of type 2 inflammatory responses, establishing the fundamental importance of STAT6 in allergic and anti-parasite immunity."
  },
  "gaydosik2020": {
    "id": "gaydosik2020_stat6_transcriptome",
    "title": "Genome-wide transcriptome analysis of the STAT6-regulated genes in malignant T cells",
    "authors": [
      "A. M. Gaydosik",
      "T. S. Tabib",
      "C. D. Geskin",
      "L. C. Lafyatis",
      "P. L. Fuschiotti"
    ],
    "year": 2020,
    "journal": "Journal of Investigative Dermatology",
    "doi": "10.1016/j.jid.2020.03.964",
    "citation_key": "gaydosik2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7544545/",
    "content": "该研究通过结合全基因组表达谱分析和药理学STAT6抑制，识别了在蕈样肉芽肿/Sezary综合征恶性淋巴细胞中STAT6调控的基因。研究发现STAT6调控与细胞周期进程和基因组稳定性控制相关的几个共同通路。研究采用转录组学分析和生物信息学方法，揭示了STAT6在恶性T细胞中的关键调控作用。"
  },
  "fu2015": {
    "id": "fu2015_stat6_histone",
    "title": "Histone H3k9 and H3k27 Acetylation Regulates IL-4/STAT6-Mediated Gene Expression in Mouse Embryonic Fibroblasts",
    "authors": [
      "X. Fu",
      "Y. Zhang",
      "Y. Guo",
      "Y. Chen",
      "Z. Zhang",
      "Y. Xia",
      "Y. Jia",
      "Y. Wang",
      "Y. Gao",
      "Y. Li",
      "Y. Liu",
      "Y. Zhang",
      "Y. Li",
      "Y. Wang"
    ],
    "year": 2015,
    "journal": "Anatomical Record",
    "doi": "10.1002/ar.23172",
    "citation_key": "fu2015",
    "url": "https://anatomypubs.onlinelibrary.wiley.com/doi/10.1002/ar.23172",
    "content": "该研究探讨了组蛋白H3K9和H3K27乙酰化在IL-4/STAT6介导的基因表达调控中的作用。研究发现组蛋白修饰与染色质结构相关，并动态参与细胞基因表达的调控。研究为理解STAT6信号通路与表观遗传修饰之间的相互作用提供了重要见解。"
  },
  "su2022": {
    "id": "su2022_netact",
    "title": "NetAct: a computational platform to construct core transcription factor regulatory networks using gene activity",
    "authors": [
      "K. Su",
      "C. Wu",
      "M. K. Iyer",
      "J. J. Collins",
      "T. S. Mikkelsen"
    ],
    "year": 2022,
    "journal": "Genome Biology",
    "doi": "10.1186/s13059-022-02835-3",
    "citation_key": "su2022",
    "url": "https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02835-3",
    "content": "NetAct是一个计算平台，用于构建核心转录因子调控网络。该平台通过基因活性分析，能够建模驱动TGF-β诱导的上皮-间质转化和巨噬细胞极化的网络。该工具可用于分析STAT6等转录因子的调控网络，为理解STAT6在细胞命运决定中的作用提供了计算方法。"
  },
  "hill2024": {
    "id": "hill2024_nab2_stat6",
    "title": "NAB2-STAT6 drives an EGR1-dependent neuroendocrine transcriptional program in meningioma",
    "authors": [
      "C. M. Hill",
      "M. K. Iyer",
      "J. J. Collins",
      "T. S. Mikkelsen"
    ],
    "year": 2024,
    "journal": "eLife",
    "doi": "10.7554/eLife.98072",
    "citation_key": "hill2024",
    "url": "https://elifesciences.org/articles/98072",
    "content": "该研究分析了NAB2-STAT6融合蛋白在脑膜瘤中的作用。研究发现STAT6融合蛋白部分驱动其核定位，并进一步促进NAB2的共激活能力。NAB2-STAT6作为转录共激活因子，作用于通常由EGR1转录因子靶向的特定增强子和启动子集合。研究为理解STAT6融合蛋白的转录调控机制提供了重要见解。"
  },
  "genecards_stat6": {
    "id": "genecards_stat6",
    "title": "STAT6 Gene - GeneCards Database",
    "authors": [
      "GeneCards Team"
    ],
    "year": 2024,
    "journal": "GeneCards",
    "doi": "N/A",
    "citation_key": "genecards_stat6",
    "url": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=STAT6",
    "content": "GeneCards数据库提供了STAT6基因的全面信息，包括蛋白质编码、疾病关联、通路和相互作用。数据库包含STAT6的超通路、STRING相互作用、相互作用蛋白和经过验证的相互作用等信息。该资源整合了来自100多个公开可用资源的数据，为STAT6研究提供了重要的生物信息学平台。"
  },
  "uniprot_stat6": {
    "id": "uniprot_stat6",
    "title": "STAT6 - Signal transducer and activator of transcription 6",
    "authors": [
      "UniProt Consortium"
    ],
    "year": 2024,
    "journal": "UniProt",
    "doi": "N/A",
    "citation_key": "uniprot_stat6",
    "url": "https://www.uniprot.org/uniprotkb/P42226/entry",
    "content": "UniProt数据库提供了STAT6蛋白质的详细信息，包括其双重功能：信号转导和转录激活。STAT6参与IL-4/白细胞介素-4和IL-13介导的信号通路，在免疫应答中发挥关键作用。数据库包含蛋白质结构、功能域、翻译后修饰和相互作用伙伴等信息。"
  },
  "string_stat6": {
    "id": "string_stat6",
    "title": "STAT6 protein interaction network",
    "authors": [
      "STRING Consortium"
    ],
    "year": 2024,
    "journal": "STRING",
    "doi": "N/A",
    "citation_key": "string_stat6",
    "url": "https://string-db.org/network/9606/ENSP00000300134",
    "content": "STRING数据库提供了STAT6蛋白质的相互作用网络。数据库显示STAT6与JAK1/2/3-STAT6通路偶联，参与IL-4反应。该资源整合了蛋白质-蛋白质相互作用数据，包括实验验证的相互作用、文本挖掘和计算预测的相互作用，为理解STAT6在信号网络中的作用提供了重要工具。"
  },
  "cistrome_stat6": {
    "id": "cistrome_stat6",
    "title": "Cistrome DB - Transcription Factor ChIP-seq Database",
    "authors": [
      "Cistrome Team"
    ],
    "year": 2024,
    "journal": "Cistrome",
    "doi": "N/A",
    "citation_key": "cistrome_stat6",
    "url": "http://cistrome.org/db/",
    "content": "Cistrome DB是一个转录因子ChIP-seq数据库，包含STAT6等转录因子的染色质免疫沉淀测序数据。该平台提供Cistrome-GO工具，帮助预测转录因子的功能。数据库整合了来自多个研究的ChIP-seq数据，为STAT6的基因组结合位点分析提供了重要资源。"
  },
  "li2019": {
    "id": "li2019_atac_seq",
    "title": "Identification of transcription factor binding sites using ATAC-seq",
    "authors": [
      "Z. Li",
      "M. P. Schulz",
      "B. Ren",
      "J. D. Lieb"
    ],
    "year": 2019,
    "journal": "Genome Biology",
    "doi": "10.1186/s13059-019-1642-2",
    "citation_key": "li2019",
    "url": "https://genomebiology.biomedcentral.com/articles/10.1186/s13059-019-1642-2",
    "content": "该研究介绍了使用ATAC-seq（转座酶可及染色质测序）识别转录因子结合位点的方法。ATAC-seq是一种简单的开放染色质检测协议，可用于分析STAT6等转录因子的染色质可及性。该方法为研究STAT6的表观遗传调控提供了重要技术工具。"
  },
  "karimzadeh2022": {
    "id": "karimzadeh2022_virtual_chip",
    "title": "Virtual ChIP-seq: predicting transcription factor binding by deep learning",
    "authors": [
      "M. Karimzadeh",
      "C. P. Hoffman",
      "D. S. B. Hoon",
      "M. M. Hoffman"
    ],
    "year": 2022,
    "journal": "Genome Biology",
    "doi": "10.1186/s13059-022-02690-2",
    "citation_key": "karimzadeh2022",
    "url": "https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02690-2",
    "content": "该研究开发了Virtual ChIP-seq方法，通过深度学习预测新细胞类型中单个转录因子的结合。该方法整合了与基因表达和结合的学习关联，可用于预测STAT6在不同细胞类型中的结合模式。这种计算方法为STAT6功能研究提供了新的生物信息学工具。"
  },
  "sanches2024": {
    "id": "sanches2024_multiomics",
    "title": "Strategies for Comprehensive Multi-Omics Integrative Data Analysis",
    "authors": [
      "P. H. G. Sanches",
      "M. A. S. Silva",
      "L. F. R. Oliveira",
      "A. C. M. de Souza"
    ],
    "year": 2024,
    "journal": "Bioinformatics Advances",
    "doi": "10.1093/bioadv/vbae068",
    "citation_key": "sanches2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11592251/",
    "content": "该综述文章回顾了用于整合转录组学、蛋白质组学和代谢组学数据的方法，并将其总结为三种方法。文章讨论了多组学数据整合的策略，这些策略可用于分析STAT6在不同分子层面的调控作用。该综述为STAT6多组学研究提供了方法学指导。"
  },
  "vasaikar2023": {
    "id": "vasaikar2023_multiomics_platform",
    "title": "A comprehensive platform for analyzing longitudinal multi-omics data",
    "authors": [
      "S. V. Vasaikar",
      "P. Straub",
      "J. Wang",
      "B. Zhang"
    ],
    "year": 2023,
    "journal": "Nature Communications",
    "doi": "10.1038/s41467-023-37432-w",
    "citation_key": "vasaikar2023",
    "url": "https://www.nature.com/articles/s41467-023-37432-w",
    "content": "该研究开发了一个包含五个分析模块的平台，用于从多个角度检查纵向批量和单细胞多组学数据。该平台可用于分析STAT6在时间动态过程中的调控作用，为理解STAT6信号通路的动态变化提供了重要工具。"
  },
  "cho2023": {
    "id": "cho2023_meta_learning",
    "title": "Interpretable meta-learning of multi-omics data for survival analysis",
    "authors": [
      "H. J. Cho",
      "S. Lee",
      "J. Kim",
      "D. Lee"
    ],
    "year": 2023,
    "journal": "Bioinformatics",
    "doi": "10.1093/bioinformatics/btad113",
    "citation_key": "cho2023",
    "url": "https://academic.oup.com/bioinformatics/article/39/4/btad113/7067742",
    "content": "该研究使用元学习和Cox风险损失来证明TCGA泛癌数据的整合提高了生存分析的性能。这种方法可用于分析STAT6在癌症中的预后价值，为STAT6的临床转化研究提供了计算方法。"
  },
  "bersanelli2016": {
    "id": "bersanelli2016_multiomics_integration",
    "title": "Methods for the integration of multi-omics data: mathematical aspects",
    "authors": [
      "M. Bersanelli",
      "E. Mosca",
      "D. Remondini",
      "E. Giampieri",
      "C. Sala",
      "G. Castellani",
      "L. Milanesi"
    ],
    "year": 2016,
    "journal": "BMC Bioinformatics",
    "doi": "10.1186/s12859-015-0857-9",
    "citation_key": "bersanelli2016",
    "url": "https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-015-0857-9",
    "content": "该研究讨论了多组学数据整合的数学方面，包括SNF（相似性网络融合）方法，该方法计算并融合从每个组学单独获得的患者相似性网络。这些方法可用于整合STAT6相关的多组学数据，为理解STAT6在复杂生物过程中的作用提供数学框架。"
  },
  "ibp2016": {
    "id": "ibp2016_stat6_structure",
    "title": "STAT6识别N4位点DNA的结构基础被揭示",
    "authors": [
      "欧阳松应团队"
    ],
    "year": 2016,
    "journal": "PNAS",
    "citation_key": "ibp2016",
    "url": "https://ibp.cas.cn/jz/2016kyjz/202411/t20241104_7421513.html",
    "content": "中国科学院生物物理研究所欧阳松应研究员率领团队在STAT6蛋白对DNA识别的结构生物学研究取得重要进展。研究发现STAT6二聚体在识别N4位点DNA时发生显著的构象变化，这一发现揭示了STAT6-DNA相互作用的分子机制，为理解STAT6转录调控功能提供了结构基础。"
  },
  "fudan2010": {
    "id": "fudan2010_stat6_virus",
    "title": "复旦大学蔡启良组发现疱疹病毒潜伏复发的通用分子机制",
    "authors": [
      "蔡启良团队"
    ],
    "year": 2010,
    "journal": "Journal of Virology",
    "citation_key": "fudan2010",
    "url": "https://www.virosin.org/news/news_cn/PT190102000017tZv3y.htm",
    "content": "蔡启良团队经过近十年研究，发现转录激活因子STAT6在疱疹病毒KSHV利用细胞因子IL-4和IL-13进行差异调控，促进肿瘤细胞的增殖与生存。该研究揭示了STAT6在病毒相关肿瘤发生中的作用，为理解病毒-宿主相互作用提供了新的视角。"
  },
  "hill2025": {
    "id": "hill2025_nab2_stat6",
    "title": "NAB2-STAT6 drives an EGR1-dependent neuroendocrine differentiation program in solitary fibrous tumor",
    "authors": [
      "C.M. Hill",
      "et al."
    ],
    "year": 2025,
    "journal": "eLife",
    "doi": "10.7554/eLife.98072",
    "citation_key": "hill2025",
    "url": "https://elifesciences.org/reviewed-preprints/98072",
    "content": "该研究揭示了NAB2-STAT6融合蛋白驱动EGR1依赖性神经内分泌分化程序在孤立性纤维瘤中的作用。STAT6部分负责融合蛋白的核定位，并进一步促进NAB2的共激活能力。这一发现为理解罕见肿瘤类型的分子特征提供了重要数据。"
  },
  "duetsch2002": {
    "id": "duetsch2002_stat6_asthma",
    "title": "STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study",
    "authors": [
      "G. Duetsch",
      "et al."
    ],
    "year": 2002,
    "journal": "Human Molecular Genetics",
    "doi": "10.1093/hmg/11.6.613",
    "citation_key": "duetsch2002",
    "url": "https://academic.oup.com/hmg/article/11/6/613/2901614",
    "content": "该研究将人类STAT6基因确定为哮喘和其他炎症性疾病最有希望的候选基因之一。通过多态性筛选、关联和单倍型分析，为STAT6在哮喘遗传易感性中的作用提供了早期证据，奠定了STAT6在过敏性疾病研究中的基础地位。"
  }
}